• צור קשר
  • הצטרפות / תשלום דמי חבר
  • פייסבוק אתר החברה
  • מטופלים משתפים
ההסתדרות הרפואית בישראל – החברה לחקר, מניעה וטיפול בטרשת עורקים
ההסתדרות הרפואית בישראל – החברה לחקר, מניעה וטיפול בטרשת עורקים
Israel Medical Association – Society for Research, Prevention and Treatment of Atherosclerosis
  • דף הבית
  • חדשות
    • ATH – Newsletter of Atherosclerosis
  • כנסים ותיעוד כנסים
    • תעוד אירועים
  • הנחיות אבחון וטיפול
  • מאמרים וסקירות
  • הצגות מקרים לדיון
  • קישורים
    • מאגרי מידע
      • כלי מידע מקצועיים Medscape
  • דף הבית
  • חדשות
    • ATH – Newsletter of Atherosclerosis
  • כנסים ותיעוד כנסים
    • תעוד אירועים
  • הנחיות אבחון וטיפול
  • מאמרים וסקירות
  • הצגות מקרים לדיון
  • קישורים
    • מאגרי מידע
      • כלי מידע מקצועיים Medscape
ההסתדרות הרפואית בישראל – החברה לחקר, מניעה וטיפול בטרשת עורקים
  • דף הבית
  • חדשות
    • ATH – Newsletter of Atherosclerosis
  • כנסים ותיעוד כנסים
    • תעוד אירועים
  • הנחיות אבחון וטיפול
  • מאמרים וסקירות
  • הצגות מקרים לדיון
  • קישורים
    • מאגרי מידע
      • כלי מידע מקצועיים Medscape
  • דף הבית
  • חדשות
    • ATH – Newsletter of Atherosclerosis
  • כנסים ותיעוד כנסים
    • תעוד אירועים
  • הנחיות אבחון וטיפול
  • מאמרים וסקירות
  • הצגות מקרים לדיון
  • קישורים
    • מאגרי מידע
      • כלי מידע מקצועיים Medscape
ראשי » חדשות » Primary Prevention Newsletter: December 2023 – International Atherosclerosis Society

Primary Prevention Newsletter: December 2023 – International Atherosclerosis Society

תאריך: 30/01/2024
 

Primary Prevention Newsletter
December 2023

 

 

 
 

IAS’ Primary Prevention newsletter includes curated, peer-reviewed content

about the effects, benefits, and harms of statins as related to atherosclerosis. Additional articles about lifestyle modifications, aspirin therapy, and new science related to alternatives for patients who are statin intolerant may also be included.

Articles are curated and commentary is provided by Peter Lansberg, MD, PhD – a Dutch lipidologist – and Rodrigo Alonso, MD, PhD – Co-Director of the Center for Advanced Metabolic Medicine and Nutrition in Santiago. The newsletter’s editorial review is provided by Raul Santos, MD, PhD – Director of the Lipid Clinic at the Heart Institute in São Paulo.

 

 

 
 

Key Publications

 

 
 

1. Observational study on the effects of statins in elderly veterans with CKD

The study, focusing on U.S. veterans older than 65 years with chronic kidney disease (CKD), stages 3 to 4, aimed to determine the association of statin initiation with all-cause mortality and major adverse cardiovascular events (MACE). It employed a target trial emulation design using a vast dataset from the Veterans Affairs Healthcare System, Medicare, and Medicaid. The study included 14,828 veterans, primarily male and white, with a mean age at CKD diagnosis of 76.9 years. Through propensity score adjustment and nonparametric bootstrapping, the analysis showed a statistically significant 9% lower risk of all-cause mortality for statin initiators compared to non-initiators, although it did not show a statistically significant reduction in MACE.

The findings challenge the growing inclination towards deprescribing statins in older adults with CKD for primary prevention. The study's strength lies in its large sample size, long follow-up, and robust methodological approach to minimize confounding. However, the predominantly male and white cohort limits the generalizability of the findings. Also, the observational design, although well-executed, inherently carries the risk of residual confounding. The study didn't evaluate the per-protocol effect size for statin use after the initial prescription or the dose or duration of statin therapy, which could further inform the clinical application of its findings.

In conclusion, the study provides compelling evidence supporting the use of statins for primary prevention of all-cause mortality in older adults with moderate CKD but raises questions about their impact on MACE. The call for a randomized clinical trial is well-founded and necessary to confirm these results and guide clinical practice. Until then, the evidence suggests a cautious approach towards deprescribing statins in this population, considering the individual patient's context and risk profile.

Statins, Mortality, and Major Adverse Cardiovascular Events Among US Veterans With Chronic Kidney Disease. JAMA network open 2023; 6:e2346373 Barayev O, Hawley CE, Wellman H et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38055276

 

 
 

2. VTE risk in post-menopausal women on HRT and statins 

The complex interplay between statin use, hormone replacement therapy (HRT), and the risk of venous thromboembolism (VTE) in perimenopausal women is reviewed in this retrospective observational study. The authors used nested case-control design based on data collected in a large US claims database. The study involved women aged 50 to 64 years taking HRT, with or without concurrent statin therapy. The robust sample size of 223,949 participants allowed for a detailed exploration of these associations.

The findings indicate that HRT alone is associated with a 53% increased risk of VTE. However, when combined with statin therapy, the risk is reduced, though not entirely mitigated. Statins alone were associated with a 12% decrease in VTE risk. Importantly, the study demonstrates a dose-response effect: higher intensity statin therapy correlates with a more significant reduction in VTE risk. The study stands out for its large, diverse cohort and detailed analysis of drug exposures. It controls for a wide range of potential confounders, including comorbidities and various lifestyle factors. Moreover, the study's design, which pairs a stringent case definition with confirmatory events, strengthens the validity of its findings. However, as a nested case-control study, it cannot establish causality. It's also limited by the typical constraints of claims data, such as lack of detailed patient characteristics and potential misclassification of exposures.

The findings are compelling but underscore the need for randomized controlled trials to confirm the potential protective role of statins in women taking HRT. This study provides valuable insights into how statin therapy might modulate the risk of VTE in women undergoing hormone therapy. The findings suggest a nuanced approach to prescribing HRT in perimenopausal women, especially those at higher cardiovascular risk, and highlight the potential of statins to improve the risk-benefit profile of hormone therapy.

Statin Use and the Risk of Venous Thromboembolism in Women Taking Hormone Therapy. JAMA network open 2023; 6:e2348213 Davis JW, Weller SC, Porterfield L et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38100102

 

 
 

3. The potential of atorvastatin to mitigate cognitive impairment

Remarkable findings in this basic science study using ApoE-/- mouse model, investigated the therapeutic potential of atorvastatin in mitigating memory deficits and brain monocyte infiltration caused by chronic hypercholesterolemia. Mild cognitive impairment (MCI) is prevalent in individuals over 60 and is exacerbated by hypercholesterolemia, leading to neuron damage and cognitive impairment through neuroinflammation, BBB dysfunction, and monocyte infiltration. The study suggests that hypercholesterolemia-induced changes, including increased plasma cholesterol, reduced Recognition Index (RI) in memory tests, decreased mobility, and downregulated PSD-95 and BDNF, are significantly reversed by atorvastatin. Moreover, atorvastatin notably represses increased brain and blood Ly6Chi CD45+ cells, plasma IL-12/IL-23, and IL-17 levels, all indicators of inflammation and immune activation.

The authors also highlight that atorvastatin prevents the increased permeability of the blood-brain barrier (BBB) and restores the expression of tight junction proteins (ZO-1 and occludin) and KLF2, a transcriptional factor regulating these proteins. This suggests its role in protecting against BBB disruption and suppressing neuroinflammation, thereby mitigating cognitive impairment. The methodology involves using aged ApoE-/- mice to mimic chronic hypercholesterolemia and assessing the effects of atorvastatin treatment on various physiological and molecular markers related to memory, inflammation, and BBB integrity.
Atorvastatin demonstrates a promising therapeutic potential in reducing memory deficits and monocyte infiltration in the brain, possibly through mechanisms involving lipid-lowering, anti-inflammatory effects, and BBB protection. This suggests its potential utility in treating hypercholesterolemia-related cognitive impairments, though further investigation is needed to understand the underlying mechanisms and its effectiveness in human subjects.

Atorvastatin mitigates memory deficits and brain monocyte infiltration in chronic hypercholesterolemia. Aging 2023; 15 Gong F, Shi Q, Mou X et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38048213

 

 
 

4. The HEARTBEAT study confirms inadequate lipid targets in high risk primary prevention patients suffering a first ASCVD event 

The HEARTBEAT study, a retrospective multicentre observational study conducted in Spain, evaluated the attainment of low-density lipoprotein cholesterol (LDL-C) targets in patients on lipid-lowering therapy (LLT) before experiencing a first major acute cardiovascular event (MACE). The study encompassed 334 patients, predominantly male and Caucasian, with a median age of 72 years, most of whom were at high or very high cardiovascular risk prior to MACE. Astonishingly, 87.5% and 89.7% of patients at high and very high cardiovascular risk, respectively, failed to achieve the LDL-C targets. Furthermore, only a small fraction had received high-intensity LLTs before MACE, indicating that patients were generally undertreated and far from lipid targets.

The significance of managing dyslipidemia, particularly LDL-C, as a major risk factor for cardiovascular disease (CVD) is well-established. Lowering LDL-C has been shown to significantly reduce the incidence of major cardiovascular events, and specific LDL-C targets have been recommended for patients based on their risk levels. However, the study reveals a concerning gap between these guidelines and real-world practices, with a high incidence of failure to meet LDL-C targets among patients on LLT for primary prevention. This suboptimal performance in reaching LDL-C targets and undertreatment highlights a significant issue in the management of CVD risk, especially considering that nearly 70% of the patients were at high or very high cardiovascular risk before their first major cardiovascular event.

The findings are in line with previous reports of suboptimal LDL-C target achievements in primary prevention in Europe and Spain. It points out the need for increased awareness and adherence to international guidelines among healthcare professionals to improve the use of LLTs in clinical practice and help more patients achieve their LDL-C goals. The authors call for action to optimize primary prevention strategies using more effective/intensive LLTs tailored to cardiovascular risk to avoid the first occurrence of MACE.

Patients who suffer a first atherosclerotic cardiovascular event while taking statins are often far off of lipid targets. Nutrition, metabolism, and cardiovascular diseases : NMCD 2023; Masana L, Díaz Moya G, Pérez de Isla L. http://www.ncbi.nlm.nih.gov/pubmed/?term=38092606

 

 
 

5. Review: statins effect on blood clotting

This is a comprehensive review on the multifaceted role of statins in blood coagulation and thromboembolic disease management. Statins have shown to exert significant anticoagulant and antiplatelet effects. These effects are attributed to the downregulation of tissue factor (TF) expression, reduced thrombin generation, impaired fibrinogen cleavage, modulation of various coagulation factors, and enhanced endothelial thrombomodulin expression. The review highlights the pleiotropic effects of statins that extend beyond cholesterol reduction, contributing to their efficacy in cardiovascular disease management.

In vitro and in vivo studies demonstrate statins' influence on platelet aggregation, TF gene expression, von Willebrand factor, D-dimer levels, and several coagulation factors. Statins also impact the protein C pathway, a critical regulator of thrombin formation, and the tissue factor pathway inhibitor (TFPI), affecting the TF-FVIIa complex activity. The review underscores the variability in statins' effects on different coagulation factors and acknowledges the need for further research to clarify these mechanisms. Clinically, statins have been associated with primary and secondary prevention of venous thromboembolism (VTE), with studies indicating a potential reduction in VTE recurrences and mortality. However, the evidence is mixed, and the review calls for more targeted intervention studies to conclusively determine statins role in VTE management. The potential risks, such as increased bleeding in certain contexts and other documented side effects like myopathy and diabetes, are also discussed. While statins antithrombotic properties are promising, their impact on VTE’s require further clarification through dedicated research. The review provides a critical understanding of statins complex role in coagulation and their potential therapeutic implications in thromboembolic disease management.

Statins Effects on Blood Clotting: A Review. Cells 2023; 12 Siniscalchi C, Basaglia M, Riva M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38067146

 

 
 

6. A study showing atorvastatin with an antihypertensive effect

Some meta-analyses have shown that statins can contribute to reduce blood pressure explained in part through the increase of nitric oxide bioavailability in vessels, and also due to some calcium channel-blocking activity observed in animal models.

This small study was designed to evaluate the antihypertensive role of atorvastatin in patients with recent diagnosis of hypertension (HTN) without history of pharmacological treatment and without any other risk factor including dyslipidemia. It included 120 healthy subjects over 35 years old were randomly assigned to amlodipine 5 mg PO daily (Am, N=60) or to amlodipine 5 mg PO plus atorvastatin 10 mg PO (Am+At, N=60). Blood pressure was measured again after 14 days of treatment. Both groups reduced systolic and diastolic blood pressure (SBP, DBP); however, a statistically significant higher decrease in mean SBP and DBL was observed in the group Am+At compared with Am (P<0.01). Mean attained SBP and DBP was lower in group Am+At.

The main conclusion of this pilot study was that the co-administration of amlodipine and atorvastatin permit a better control of blood pressure compared to amlodipine alone, although synergistic effect of both medications was not studied. Some previous studies have shown similar results in patients with chronic hypertension with poor control of BP, and with dyslipidemia using different statins. The main limitations of this study were the small sample size, it was not controlled with placebo, the short period of follow-up, and lipid profile is not provided. Therefore, further studies are necessary to address the efficacy and safety of the combination of amlodipine and atorvastatin as initial treatment in patients with recent diagnosis of HTN and without dyslipidemia.

Atorvastatin as an Antihypertensive Agent: A Pilot Study. Cureus 2023; 15:e49532 Ali N, Faheem M, Ullah H et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38156151

 

 
 

7. Statin rechallenge, an option in patients with statin associated muscle symptoms

Statins are a cornerstone in atherosclerotic cardiovascular disease prevention; however, one of the most frequent causes of treatment interruption are statin associated muscle symptoms (SAMS). There is a challenge in the diagnosis and management of this condition to avoid unnecessary treatment interruption. Statin rechallenge (the same statin in lower doses, intermittent dose, or another statin) is one of the strategies used to the management of SAMS. This systematic review and meta-analysis was aimed to evaluate if statin intolerant individuals can successfully resume statins when statins rechallenge is blinded.

Eight randomized studies of 53 studies, including over 900 unique individuals, met the inclusion criteria. From those, 36% of participants previously believed to be intolerant were unable to tolerate a statin on blinded rechallenge versus 26% on placebo [RR 1.40, 95% CI, 1.23 to 1.60, I2 = 0%, number needed to harm 10]. Tolerance seems not to change over time, and there were no differences in mean myalgia or global symptom score between statin and placebo users. The study has some limitations like the small numbers of trials in the analysis, possible attrition bias, and in some cases the possibility of carryover effect in some cross-over trials. However, findings of this study appear to be robust; risk of bias was low, sensitivity analysis found little differences between groups, and heterogeneity was low even with the variability in trial design. Since a practical point of view, and as suggested by authors, clinicians should consider in patients with SAMS first to re-introduce statins in different schemes: lower doses, intermittent doses, or change statin, before moving to non-statins drugs.

Intolerance upon statin rechallenge: A systematic review and meta-analysis of randomized controlled trials. PLoS One 2023; 18:e0295857 Kraut R, Wierenga F, Molstad E et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38128013

 

 
 

8. Statins have cognitive benefits in patients with dementia

A dysregulation of brain cholesterol homeostasis has been proposed in the pathogenesis of Alzheimer’s disease (AD), including interference with the amyloidogenic AB pathway, and impairment of cerebral blood flow, among others. The role of statins in preventing dementia or ameliorate cognitive decline in patients with dementia is still unclear. The adverse cognitive effects of statins described in some few studies have not been confirmed in large systematic reviews and meta-analyses.

In this exploratory study, authors evaluated the association between statin use and cognitive decline over time in a cohort of 15,586 patients diagnosed with AD or mixed AD dementia from the Swedish registry for dementia (SveDem). Only patients with known hyperlipidemia in the 10 years before the diagnosis, or those with statin prescription during the six months before the diagnosis were included in the analysis. Patients were followed-up until death, emigration or end of follow-up (Oct 2018), and the main outcome was cognitive decline using the mini mental state examination (MMSE). The main results of this longitudinal study were: 1) a dose-dependent cognitive benefit in statin users during 3 years vs. non-users; 2) a slower MMSE decline over time in patients with simvastatin, compared to atorvastatin and rosuvastatin, more evident in younger patient (< 79.5 years). No differences related to statin lipophilicity was observed. There was inconsistency in findings in incident statin-users explained in part by the time-dependent non-linear association between effect of statins on cognitive processes or through differences and selection of these users.

The main conclusion of this study are: 1) statins are not detrimental for cognition over time; and 2) statins might have cognitive benefit in patients with indication of long-term use. The limitations of the study are that only association was reported (not causality) and as an exploratory analysis, it requires confirmation studies. Moreover, some important variables such as lipid levels, ApoE status and some genetic polymorphisms population-specific were not available. Further research regarding pathogenesis of dementia, the role of lipid dysregulation and genetic factors, and the timing of statin prescription are needed.

Statins and cognitive decline in patients with Alzheimer's and mixed dementia: a longitudinal registry-based cohort study. Alzheimer's research & therapy 2023; 15:220 Petek B, Häbel H, Xu H et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38115091

 

 
 

9. Type and intensity of statin treatment do matter in the prevention of dementia in T2DM

This population-based cohort study investigated the relationship between statin use and risk of dementia in more than 830,000 patients older than 60 years old with type 2 diabetes (T2D) from the Taiwan’s National Health Insurance Research Database (NHIRD). The primary outcome variable was the risk of dementia, diagnosis validated by specialists. The inverse probability of treatment weighting (IPTW) Cox hazards model was used as the tool to quantify the relationship between statins and dementia. Moreover, the type of statin, intensity of treatment measured as average statin dose, and cumulative daily dose were analyzed. There were no differences in baseline characteristics among statin-users (n=414,110) and non-users (n=409,642). After a median follow-up of 7.94 years for statin users, and 8.62 years for non-users, the incidence of dementia was significantly lower in statin users, with an incident rate ratio of 0,58 (CI 0.57,0.59), p<0.001. Statin users showed a significant reduction in dementia risk with an adjusted hazard ratio (aHR) of 0.47 (95% CI 0.46,0.48). The rank order of statins for reducing risk of dementia was pitavastatin>rosuvastatin> pravastatin> atorvastatin> simvastatin> fluvastatin> lovastatin. On the other hand, patients with higher cumulative defined daily dose per year had greater reduction in dementia risk (aHR 0.20 in Q4 and 0.72 in Q1, p<0.001. The unique pharmacokinetic properties of pitavastatin, including its efficient penetration of the blood-brain barrier, and some neuroprotective and anti-inflammatory properties may contribute to preserve cognitive function with this statin.

As pointed out by authors, the study has strengths and limitations. The large sample of patients enhanced the statistical power, although only people from Taiwan were included. The intensity of statin treatment could be analyzed, and the IPTW cox multivariate models permitted a robust evaluation of statin use and main outcome. As, in this type of study, the main limitation was that in the database not all variables of interest (lipid levels, lifestyle factors) were available, and the limited number of events in some subgroups of statin users could be a bias.

In conclusion, statins reduce the risk of dementia, and this reduction depends in part by the type of statin, intensity of use, and cumulative dose-dependent effect. However, further investigations are warranted to elucidate the detailed mechanisms underlying the protective effects of different statins against dementia.

Protective Effects Against Dementia Undergo Different Statin Type, Intensity, and Cumulative Dose in Older Adult Type 2 Diabetes Mellitus Patients. Journal of the American Medical Directors Association 2023; Sun M, Chen WM, Wu SY, Zhang J. http://www.ncbi.nlm.nih.gov/pubmed/?term=38128583

 

 
 

10. Metabolic regulation of immune cells in the pathogenesis of atherosclerosis, and the role of statins

Atherosclerosis is a chronic immune-inflammatory condition characterized by the build-up of plaque (fatty deposits) within the arterial intima and is the main cause of cardiovascular disease. The accumulation of cholesterol and other lipids within the arterial wall due to foam cells accumulation is an initial stage of this process. Multiple cell types from the artery wall, and circulating cells are implicated in the pathogenesis of atherosclerosis, especially inflammatory and immune cells. The activation and dysfunction of endothelial cells (EC) permits the infiltration of monocytes that undergo differentiation into dendritic cells linking innate and adaptative immune response, and also to proinflammatory macrophages contributing to the progression of the disease.

This review provides a comprehensive overview of the metabolic regulation of cells implicated in atherosclerosis, and how they contribute in the pathogenesis of the disease through cell activation, proliferation, differentiation, and secretion of cytokines and other immune factors depending on microenvironment. Hypoxic conditions produce alterations in the energy metabolism of cells, enhancing glycolysis as source of energy, impairing fatty acid synthesis, and altering amino-acid metabolism. Inflammatory pathways and lipid accumulation within plaques are linked to migration and proliferation of cells, and different inflammatory responses and their balance can affect vascular permeability, and plaque stability.

Furthermore, the authors discuss the effects of statins in the function of different cells in the plaque influencing the inflammatory response and plaque stability, contributing to clinical events reduction. Beyond lowering LDL-cholesterol, statins promote nitric oxide (NO) synthesis in endothelial cells, improve EC function, and inhibit smooth muscle cells proliferation and apoptosis. Other effects of statins on inflammatory cells, platelets, and SMC are explained deeply. They also discuss briefly the role of other medications used in cardiovascular disease such as anti-hypertensive, hypoglycaemic, aspirin, used in combination with statins in the treatment of atherosclerosis.

Although much progress has been made in the understanding of atherosclerosis pathogenesis, and effective treatments have been developed to reduce lipid levels, and other cardiovascular risk factors, with a demonstrated efficacy in reducing clinical events, knowledge of the metabolic processes and inflammatory interaction between cells and plaque microenvironment is more limited, and more research in needed in this field.

Metabolic changes with the occurrence of atherosclerotic plaques and the effects of statins. Frontiers in immunology 2023; 14:1301051 Zhao L, Ma D, Wang L et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38143759

 

 

 
 

Additional Publications

 

 
 

Add on treatments

  1. Trends in Upper Gastrointestinal Bleeding in Patients on Primary Prevention Aspirin: A Nationwide Emergency Department Sample Analysis, 2016-2020. Am J Med 2023; 136:1179-1186.e1171 Li DK, Laine L, Shung DL. http://www.ncbi.nlm.nih.gov/pubmed/?term=37696350
  2. Eicosapentaenoic and docosahexaenoic acid supplementation and coronary artery calcium progression in patients with coronary artery disease: A secondary analysis of a randomized trial. Atherosclerosis 2023; 387:117388 Hariri E, Asbeutah AA, Malik A et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38056242
  3. Effect of statins combined with PCSK9 inhibitors on the prognosis of patients with acute coronary syndromes after interventional therapy. Cell Mol Biol (Noisy-le-grand) 2023; 69:262-267 Shi L, Ye Z, Gu Q, Li Y. http://www.ncbi.nlm.nih.gov/pubmed/?term=38063128
  4. Ezetimibe and atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Frontiers in cardiovascular medicine 2023; 10:1269172 Omidi F, Rahmannia M, Shahidi Bonjar AH et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38075958
  5. Rationale and design of a randomized controlled trial: The effect of intensive lipid-lowering therapy with PCSK9 inhibitor on endothelial-coverage of stent strut after percutaneous coronary intervention (PCI) for patients with acute coronary syndrome (ACS): Optical coherence tomography (OCT) study (PIECES-OCT study). Heliyon 2023; 9:e22222 Yin Z, Li ZF, Zhang WJ et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38045163
  6. Aspirin use for primary prevention in older adults. J Am Geriatr Soc 2023; 71:3927-3929 Luepker RV, Van't Hof JR, Eder M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=37596891
  7. Polypill Therapy for Cardiovascular Disease Prevention and Combination Medication Therapy for Hypertension Management. Journal of clinical medicine 2023; 12 Narita K, Hoshide S, Kario K. http://www.ncbi.nlm.nih.gov/pubmed/?term=38068278
  8. Impact of atorvastatin and mesenchymal stem cells combined with ivermectin on murine trichinellosis. Parasitol Res 2023; 123:57 Hassan ZR, El-Sayed S, Zekry KM et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38105357
  9. Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review. Yonsei medical journal 2024; 65:19-26 Kang Y, Park JM, Lee SH. http://www.ncbi.nlm.nih.gov/pubmed/?term=38154476

Atherosclerosis – Plaque – Imaging

  1. Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national study. Am J Prev Cardiol 2024; 17:100611 Nasir K, Mszar R, Cainzos-Achirica M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38125206
  2. Cost-Effectiveness of the Use of the Coronary Calcium Score in Primary Prevention as a Guide for the Therapeutic Decision. Arquivos brasileiros de cardiologia 2023; 120:e20230542 Nascimento CRD, Santos JM, Mendes R et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38126486
  3. Eicosapentaenoic and docosahexaenoic acid supplementation and coronary artery calcium progression in patients with coronary artery disease: A secondary analysis of a randomized trial. Atherosclerosis 2023; 387:117388 Hariri E, Asbeutah AA, Malik A et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38056242
  4. Relation between Coronary Artery Calcium Score and Cardiovascular Events in Hodgkin Lymphoma Survivors: A Cross-Sectional Matched Cohort Study. Cancers 2023; 15 Polomski EAS, Heemelaar JC, de Graaf MA et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38136376
  5. Retracted: Additional Acupuncture Confers a Favorable Long-Term Prognosis for Elderly Hypertensive Patients with Carotid Atherosclerosis after Atorvastatin Treatment. Evidence-based complementary and alternative medicine : eCAM 2023; 2023:9780584 And Alternative Medicine EC. http://www.ncbi.nlm.nih.gov/pubmed/?term=38074848
  6. Ezetimibe and atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Frontiers in cardiovascular medicine 2023; 10:1269172 Omidi F, Rahmannia M, Shahidi Bonjar AH et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38075958
  7. Metabolic changes with the occurrence of atherosclerotic plaques and the effects of statins. Frontiers in immunology 2023; 14:1301051 Zhao L, Ma D, Wang L et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38143759
  8. Pravastatin promotes type 2 diabetes vascular calcification through activating intestinal Bacteroides fragilis to induce macrophage M1 polarization. Journal of diabetes 2023; Chen C, Liang ZF, He YQ et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38112268
  9. Using Artificial Intelligence to Semi-Quantitate Coronary Calcium as an 'Incidentaloma' on Non-Gated, Non-Contrast CT Scans, A Single-Center Descriptive Study in West Michigan. Spartan Med Res J 2023; 8:89132 Kerndt CC, Chopra R, Weber P et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38084339
  10. Aortic Arch Plaques and the Long-Term Risk of Stroke and Cardiovascular Events in the Statin Era. Stroke 2023; Yoshida Y, Jin Z, Mannina C et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38063018

Atorvastatin/Rosuvastatin

  1. Atorvastatin mitigates memory deficits and brain monocyte infiltration in chronic hypercholesterolemia. Aging 2023; 15 Gong F, Shi Q, Mou X et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38048213
  2. A Prospective Study of the Effect and Safety of Atorvastatin on the Recurrence of Chronic Subdural Hematoma after Burr Hole Surgery. Asian J Neurosurg 2023; 18:567-572 Bumpetch D, Sitthinamsuwan B, Nunta-Aree S. http://www.ncbi.nlm.nih.gov/pubmed/?term=38152511
  3. Differential effect of atorvastatin and pravastatin on thoracic spine attenuation: A sub-analysis of a randomized clinical trial. Atherosclerosis 2023; 388:117425 Raggi P, Takyar FM, Gadiyaram V et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38109819
  4. Influence of the rs4238001 Genetic Polymorphism of the SR-B1 Gene on Serum Lipid Levels and Response to Rosuvastatin in Myocardial Infarction Iraqi Patients. Biochemical genetics 2023; Abdulfattah SY, Alagely HS, Samawi FT. http://www.ncbi.nlm.nih.gov/pubmed/?term=38133857
  5. Inhibiting cholesterol de novo synthesis promotes hepatocellular carcinoma progression by upregulating prostaglandin E synthase 2-mediated arachidonic acid metabolism under high fatty acid conditions. Cancer science 2023; Zhao Z, Liu X, Xiang Y et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38081591
  6. Influence of a Short Course of Ritonavir Used as Booster in Antiviral Therapies Against SARS-CoV-2 on the Exposure of Atorvastatin and Rosuvastatin. Cardiovasc Drugs Ther 2023; Krohmer E, Rohr BS, Stoll F et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38112932
  7. Effect of statins combined with PCSK9 inhibitors on the prognosis of patients with acute coronary syndromes after interventional therapy. Cell Mol Biol (Noisy-le-grand) 2023; 69:262-267 Shi L, Ye Z, Gu Q, Li Y. http://www.ncbi.nlm.nih.gov/pubmed/?term=38063128
  8. Lipophilic Statins Eliminate Senescent Endothelial Cells by inducing Anoikis-Related Cell Death. Cells 2023; 12 Belakova B, Wedige NK, Awad EM et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38132158
  9. Hydrogels Loaded with Atorvastatin-Metal Organic Framework Have a Preventive Effect on Coronary Heart Disease. Chem Biodivers 2023:e202301511 Bai X, Jiang J, Tu S, Zhang W. http://www.ncbi.nlm.nih.gov/pubmed/?term=38063816
  10. Retracted: Related Factors of Cerebral Hemorrhage after Cerebral Infarction and the Effect of Atorvastatin Combined with Intensive Nursing Care. Comput Math Methods Med 2023; 2023:9817935 Methods In Medicine CAM. http://www.ncbi.nlm.nih.gov/pubmed/?term=38094432
  11. Atorvastatin as an Antihypertensive Agent: A Pilot Study. Cureus 2023; 15:e49532 Ali N, Faheem M, Ullah H et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38156151
  12. Atorvastatin exerts dual effects of lesion regression and ovarian protection in the prevention and treatment of endometriosis. Eur J Pharmacol 2023:176261Qin X, Wang Q, Xu D et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38141938
  13. Retracted: Additional Acupuncture Confers a Favorable Long-Term Prognosis for Elderly Hypertensive Patients with Carotid Atherosclerosis after Atorvastatin Treatment. Evidence-based complementary and alternative medicine : eCAM 2023; 2023:9780584 And Alternative Medicine EC. http://www.ncbi.nlm.nih.gov/pubmed/?term=38074848
  14. Corrigendum to "Atorvastatin induced hepatic oxidative stress and apoptotic damagevia MAPKs, mitochondria, calpain and caspase12 dependent pathways" [Food Chem. Toxicol. 83 (2015) 36-47]. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2023; 183 Suppl 1:114301 Pal S, Ghosh M, Ghosh S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38052113
  15. Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial. Hepatol Commun 2023; 7 Kronborg TM, Schierwagen R, Trošt K et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38051553
  16. Effect of systemic atorvastatin on bone regeneration in critical-sized defects in hyperlipidemia: an experimental study. International journal of implant dentistry 2023; 9:50 Öztürk K, Kuzu TE, Ayrıkçil S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38097856
  17. Abnormal Cholesterol Metabolism and Lysosomal Dysfunction Induce Age-Related Hearing Loss by Inhibiting mTORC1-TFEB-Dependent Autophagy. Int J Mol Sci 2023; 24 Lee YY, Ha J, Kim YS et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38139347
  18. Significant progress in improving Atorvastatin dissolution rate: Physicochemical characterization and stability assessment of self-dispersible Atorvastatin/Tween 80® nanocrystals formulated through wet milling and freeze-drying. Int J Pharm 2023; 650:123720 Rossetti A, Real DA, Barrientos BA et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38110014
  19. Protective Effects Against Dementia Undergo Different Statin Type, Intensity, and Cumulative Dose in Older Adult Type 2 Diabetes Mellitus Patients. Journal of the American Medical Directors Association 2023; Sun M, Chen WM, Wu SY, Zhang J. http://www.ncbi.nlm.nih.gov/pubmed/?term=38128583
  20. Effect of three-day atorvastatin administration on coagulation factors in patients with prior venous thromboembolism and healthy subjects. A preliminary study. Journal of cardiovascular pharmacology 2023; Stępień K, Żółciński M, Ząbczyk M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38117119
  21. Comparison of the efficacy and safety of Shanhuang Jiangzhi tablets and atorvastatin in the treatment of patients with hyperlipidaemia. J Health Popul Nutr 2023; 42:143 Sun G, Liang X. http://www.ncbi.nlm.nih.gov/pubmed/?term=38098069
  22. Prevalent Variants in the LDLR Gene Impair Responsiveness to Rosuvastatin among Family Members of Patients with Premature Myocardial Infarction. Journal of personalized medicine 2023; 13 Kien NT, Nghia TT, Hoang NM et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38138952
  23. High-throughput target trial emulation for Alzheimer's disease drug repurposing with real-world data. Nature communications 2023; 14:8180 Zang C, Zhang H, Xu J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38081829
  24. The evaluation of atorvastatin as an adjunct to fluconazole for the anti-fungal prophylaxis in acute myeloid leukemia: a multicenter, triple-blinded, randomized clinical trial. Naunyn-Schmiedeberg's archives of pharmacology 2023; Saber-Moghaddam N, Nodeh MM, Ghavami V et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38095652
  25. Impact of atorvastatin and mesenchymal stem cells combined with ivermectin on murine trichinellosis. Parasitol Res 2023; 123:57 Hassan ZR, El-Sayed S, Zekry KM et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38105357
  26. ASSOCIATION OF SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1 GENE POLYMORPHISM WITH RESPONSE TO ATORVASTATIN AND ASSOCIATED MYOPATHY IN IRAQI DYSLIPIDEMIA PATIENTS. Pol Merkur Lekarski 2023; 51:496-503 Dheyaa Aziz N, Abbood SH, Al-Mayali AH, Hadi NR. http://www.ncbi.nlm.nih.gov/pubmed/?term=38069850
  27. Effect of Berberine on Pharmacokinetics and Pharmacodynamics of Atorvastatin in Hyperlipidemia Rats. Xenobiotica 2023:1-27 Wu F, Cui M, Wang S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38054840
  28. Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review. Yonsei medical journal 2024; 65:19-26 Kang Y, Park JM, Lee SH. http://www.ncbi.nlm.nih.gov/pubmed/?term=38154476

Basic science

  1. Atorvastatin mitigates memory deficits and brain monocyte infiltration in chronic hypercholesterolemia. Aging 2023; 15 Gong F, Shi Q, Mou X et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38048213
  2. Discovery of Natural Potent HMG-CoA Reductase Degraders for Lowering Cholesterol. Angew Chem Int Ed Engl 2023:e202313859 Su XZ, Zhang LF, Hu K et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38055195
  3. Simvastatin Enhances the Radiosensitivity of Androgen-independent Prostate Cancer Cells via Inhibition of RAD51 Expression. Anticancer research 2024; 44:93-98 Oka D, Sekine Y, Tsuji Y et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38159995
  4. Fabrication and characterizations of simvastatin-containing mesoporous bioactive glass and molybdenum disulfide scaffold for bone tissue engineering. APL Bioeng 2023; 7:046115 Murugan SS, Dalavi PA, Surya S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38058994
  5. Simvastatin/hydrogel-loaded 3D-printed titanium alloy scaffolds suppress osteosarcoma via TF/NOX2-associated ferroptosis while repairing bone defects. Bioact Mater 2024; 33:223-241Jing Z, Yuan W, Wang J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38045570
  6. The Blocking of Drug Resistance Channels by Selected Hydrophobic Statins in Chemoresistance Human Melanoma. Biomolecules 2023; 13 Placha W, Suder P, Panek A et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38136555
  7. Inhibiting cholesterol de novo synthesis promotes hepatocellular carcinoma progression by upregulating prostaglandin E synthase 2-mediated arachidonic acid metabolism under high fatty acid conditions. Cancer science 2023; Zhao Z, Liu X, Xiang Y et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38081591
  8. Lipophilic Statins Eliminate Senescent Endothelial Cells by inducing Anoikis-Related Cell Death. Cells 2023; 12Belakova B, Wedige NK, Awad EM et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38132158
  9. Hydrogels Loaded with Atorvastatin-Metal Organic Framework Have a Preventive Effect on Coronary Heart Disease. Chem Biodivers 2023:e202301511 Bai X, Jiang J, Tu S, Zhang W. http://www.ncbi.nlm.nih.gov/pubmed/?term=38063816
  10. Enhanced Neuroprotective Synergy of Atorvastatin and Magnesium L-Threonate in a Rat Model of Alzheimer's Disease Induced by Aluminum Chloride. Cureus 2023; 15:e48400 Gangoda DM, Saiyed MS, Pathan SR et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38074017
  11. Identification of 4-amino-2-Pyridones as new potent PCSK9 inhibitors: From phenotypic hit discovery to in vivo tolerability. European journal of medicinal chemistry 2023; 265:116063 Giannessi L, Lupo MG, Rossi I et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38160616
  12. Corrigendum to "Atorvastatin induced hepatic oxidative stress and apoptotic damagevia MAPKs, mitochondria, calpain and caspase12 dependent pathways" [Food Chem. Toxicol. 83 (2015) 36-47]. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2023; 183 Suppl 1:114301 Pal S, Ghosh M, Ghosh S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38052113
  13. Determination of nine cardiovascular drugs in human plasma by QuEChERS-UPLC-MS/MS. Heliyon 2023; 9:e22543 Jin C, Wang T, Zhao T et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38094060
  14. Development of a Microminipig Model of Atherosclerosis for the Evaluation of a HMGCR Inhibitor. In Vivo 2024; 38:98-106 Yamada T, Kawaguchi H, Matsuoka A et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38148058
  15. 3D printed polylactic acid-based nanocomposite scaffold stuffed with microporous simvastatin-loaded polyelectrolyte for craniofacial reconstruction. International journal of biological macromolecules 2023; 258:128917 Tavakoli M, Salehi H, Emadi R et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38134992
  16. Effect of systemic atorvastatin on bone regeneration in critical-sized defects in hyperlipidemia: an experimental study. International journal of implant dentistry 2023; 9:50Öztürk K, Kuzu TE, Ayrıkçil S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38097856
  17. Inhibitors of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Decrease the Growth, Ergosterol Synthesis and Generation of petite Mutants in Candida glabrata and Candida albicans. Int J Mol Sci 2023; 24 Andrade-Pavón D, Sánchez-Sandoval E, Tamariz J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38069194
  18. Lovastatin Treatment Inducing Apoptosis in Human Pancreatic Cancer Cells by Inhibiting Cholesterol Rafts in Plasma Membrane and Mitochondria. Int J Mol Sci 2023; 24 Gyoten M, Luo Y, Fujiwara-Tani R et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38069135
  19. Abnormal Cholesterol Metabolism and Lysosomal Dysfunction Induce Age-Related Hearing Loss by Inhibiting mTORC1-TFEB-Dependent Autophagy. Int J Mol Sci 2023; 24 Lee YY, Ha J, Kim YS et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38139347
  20. Significant progress in improving Atorvastatin dissolution rate: Physicochemical characterization and stability assessment of self-dispersible Atorvastatin/Tween 80® nanocrystals formulated through wet milling and freeze-drying. Int J Pharm 2023; 650:123720 Rossetti A, Real DA, Barrientos BA et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38110014
  21. Pravastatin promotes type 2 diabetes vascular calcification through activating intestinal Bacteroides fragilis to induce macrophage M1 polarization. Journal of diabetes 2023; Chen C, Liang ZF, He YQ et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38112268
  22. miR-612 Enhances RSL3-Induced Ferroptosis of Hepatocellular Carcinoma Cells via Mevalonate Pathway. J Hepatocell Carcinoma 2023; 10:2173-2185 Xing K, Bian X, Shi D et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38084209
  23. Computer-Aided, Resistance Gene-Guided Genome Mining for Proteasome and HMG-CoA Reductase Inhibitors. J Ind Microbiol Biotechnol 2023; Jenkinson CB, Podgorny AR, Zhong C, Oakley BR. http://www.ncbi.nlm.nih.gov/pubmed/?term=38061800
  24. Targeted Degradation of PCSK9 In Vivo by Autophagy-Tethering Compounds. Journal of medicinal chemistry 2023; Ouyang Z, Ma M, Zhang Z et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38112492
  25. Targeting the CCL2-CCR2 signaling pathway: potential implications of statins beyond cardiovascular diseases. The Journal of pharmacy and pharmacology 2023; Gholamalizadeh H, Ensan B, Sukhorukov VN, Sahebkar A. http://www.ncbi.nlm.nih.gov/pubmed/?term=38127312
  26. Combined quercetin and simvastatin attenuate hepatic fibrosis in rats by modulating SphK1/NLRP3 pathways. Life sciences 2023:122349 Salama YA, Hassan HM, El-Gayar AM, Abdel-Rahman N. http://www.ncbi.nlm.nih.gov/pubmed/?term=38128755
  27. A novel sustainable second-derivative synchronous spectrofluorimetric method for the simultaneous determination of olmesartan medoxomil and rosuvastatin calcium in bulk and formulations: Integrated greenness and whiteness evaluation. Luminescence : the journal of biological and chemical luminescence 2023; Batakoushy HA, Nasr ZA, Soliman MM et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38062646
  28. Simvastatin Differentially Modulates Glial Functions in Cultured Cortical and Hypothalamic Astrocytes Derived from Interferon α/β Receptor Knockout mice. Neurochemical research 2023; Bobermin LD, Sesterheim P, da Costa DS et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38063948
  29. Simvastatin restores pulmonary endothelial function in the setting of pulmonary over-circulation. Nitric Oxide 2023; 142:58-68 Boehme JT, Sun X, Lu Q et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38061411
  30. Impact of atorvastatin and mesenchymal stem cells combined with ivermectin on murine trichinellosis. Parasitol Res 2023; 123:57 Hassan ZR, El-Sayed S, Zekry KM et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38105357
  31. Effect of bisphosphonates and statins on the in vitro radiosensitivity of breast cancer cell lines. Pharmacological reports : PR 2023; Bodgi L, Bou-Gharios J, Azzi J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38151641
  32. Role of individual and combined impact of simvastatin and α-TCP in rat calvarial bone defect: An experimental study. Saudi Dent J 2023; 35:861-868 Sugumaran S, Selvam D, Nivedhitha MS et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38077229
  33. Erratum to atorvastatin inhibits pancreatic cancer cells proliferation and invasion likely by suppressing neurotrophin receptor signaling. Transl Cancer Res 2023; 12:3220-3221. http://www.ncbi.nlm.nih.gov/pubmed/?term=38130299
  34. Effect of Berberine on Pharmacokinetics and Pharmacodynamics of Atorvastatin in Hyperlipidemia Rats. Xenobiotica 2023:1-27 Wu F, Cui M, Wang S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38054840

Cancer

  1. Simvastatin Enhances the Radiosensitivity of Androgen-independent Prostate Cancer Cells via Inhibition of RAD51 Expression. Anticancer research 2024; 44:93-98 Oka D, Sekine Y, Tsuji Y et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38159995
  2. The Blocking of Drug Resistance Channels by Selected Hydrophobic Statins in Chemoresistance Human Melanoma. Biomolecules 2023; 13 Placha W, Suder P, Panek A et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38136555
  3. Statin use and mortality risk in Asian patients with prostate cancer receiving androgen deprivation therapy: A population-based cohort study. Cancer medicine 2023; Lee YHA, Chan JSK, Hui JMH et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38140773
  4. Inhibiting cholesterol de novo synthesis promotes hepatocellular carcinoma progression by upregulating prostaglandin E synthase 2-mediated arachidonic acid metabolism under high fatty acid conditions. Cancer science 2023; Zhao Z, Liu X, Xiang Y et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38081591
  5. Relation between Coronary Artery Calcium Score and Cardiovascular Events in Hodgkin Lymphoma Survivors: A Cross-Sectional Matched Cohort Study. Cancers 2023; 15 Polomski EAS, Heemelaar JC, de Graaf MA et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38136376
  6. Retracted: Simvastatin in the Treatment of Colorectal Cancer: A Review. Evidence-based complementary and alternative medicine : eCAM 2023; 2023:9767203 And Alternative Medicine EC. http://www.ncbi.nlm.nih.gov/pubmed/?term=38093875
  7. Lovastatin Treatment Inducing Apoptosis in Human Pancreatic Cancer Cells by Inhibiting Cholesterol Rafts in Plasma Membrane and Mitochondria. Int J Mol Sci 2023; 24 Gyoten M, Luo Y, Fujiwara-Tani R et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38069135
  8. The relationship between statin administration timing and survival outcomes in patients with cancer receiving immune checkpoint blockade. J Chemother 2023:1-6 Wang Z, See XY, Chiang CH et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38062978
  9. miR-612 Enhances RSL3-Induced Ferroptosis of Hepatocellular Carcinoma Cells via Mevalonate Pathway. J Hepatocell Carcinoma 2023; 10:2173-2185 Xing K, Bian X, Shi D et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38084209
  10. Enhanced therapeutic efficacy of doxorubicin/cyclophosphamide in combination with pitavastatin or simvastatin against breast cancer cells. Medical oncology (Northwood, London, England) 2023; 41:7 Dewidar SA, Hamdy O, Soliman MM et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=3805137
  11. Effect of bisphosphonates and statins on the in vitro radiosensitivity of breast cancer cell lines. Pharmacological reports : PR 2023; Bodgi L, Bou-Gharios J, Azzi J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38151641
  12. Statin use reduces radiation-induced stroke risk in advanced nasopharyngeal carcinoma patients. Radiother Oncol 2023; 191:110067 Lin CY, Chang CL, Lin KC et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38142934
  13. Erratum to atorvastatin inhibits pancreatic cancer cells proliferation and invasion likely by suppressing neurotrophin receptor signaling. Transl Cancer Res 2023; 12:3220-3221. http://www.ncbi.nlm.nih.gov/pubmed/?term=38130299

Children

  1. Rate and Cause of Sudden Cardiac Death in the Young During the COVID-19 Pandemic and Vaccination. Circulation 2023; 148:2069-2071 De Gaspari M, Fedeli U, Saia M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38109343
  2. Efficacy and Safety of Statin Treatment in Children with Familial Hypercholesterolemia: Outcomes of 20 Years of Experience. Journal of clinical medicine 2023; 12 Motkowski R, Abramowicz P, Kubalska J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38068249
  3. Uncertain Benefit of Statins in Pediatric Heart Transplant Recipients: A PHTS Analysis. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2023; Townsend M, Khoury M, Devin Koehl M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38065240
  4. [Study on vaccination in patients with Kawasaki disease]. Zhonghua Er Ke Za Zhi 2023; 61:1148-1151 Xie LP, Liu F, Huang GY. http://www.ncbi.nlm.nih.gov/pubmed/?term=38018056

Cost-effectiveness

  1. Cost-Effectiveness of the Use of the Coronary Calcium Score in Primary Prevention as a Guide for the Therapeutic Decision. Arquivos brasileiros de cardiologia 2023; 120:e20230542 Nascimento CRD, Santos JM, Mendes R et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38126486

CVD

  1. Association of health information technology-driven multidisciplinary approaches with low-density lipoprotein cholesterol target achievement in patients with an acute coronary syndrome. Am J Prev Cardiol 2024; 17:100613 Chen YS, Lin HH, Tsai HY et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38077651
  2. Cardiovascular Events After Coronavirus Disease 2019 Vaccinations Versus Long Coronavirus Disease. Anatol J Cardiol 2023; 27:735-736 Jargin SV. http://www.ncbi.nlm.nih.gov/pubmed/?term=37842757
  3. Statin therapy and outcome in Takotsubo syndrome patients: Results from the multicenter international GEIST registry. Atherosclerosis 2023; 389:117421 Novo G, Arcari L, Stiermaier T et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38134646
  4. Influence of the rs4238001 Genetic Polymorphism of the SR-B1 Gene on Serum Lipid Levels and Response to Rosuvastatin in Myocardial Infarction Iraqi Patients. Biochemical genetics 2023; Abdulfattah SY, Alagely HS, Samawi FT. http://www.ncbi.nlm.nih.gov/pubmed/?term=38133857
  5. Relation between Coronary Artery Calcium Score and Cardiovascular Events in Hodgkin Lymphoma Survivors: A Cross-Sectional Matched Cohort Study. Cancers 2023; 15 Polomski EAS, Heemelaar JC, de Graaf MA et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38136376
  6. Kalyani RR, Everett BM, Perreault L, Michos ED. Heart Disease and Diabetes. In: Diabetes in America. Edited by: Lawrence JM, Casagrande SS, Herman WH et al. Bethesda (MD) Advisory Committee. Dr. Everett has received consulting fees from Circulation (Associate Editor), Eli Lilly & Co, Gilead Sciences, Ipsen Biosciences Inc, Janssen (Johnson & Johnson), Provention Bio, and UpToDate (royalties for peer review content). Dr. Everett is a co-investigator on a grant funded by Novo Nordisk, which is paid to his institution. Dr. Perrault reported no conflicts of interest. Dr. Michos has received consulting fees from AstraZeneca, Amarin, Amgen, Bayer, Boehringer Ingelheim, Edwards Lifesciences, Esperion Therapeutics, Medtronic, Novartis, Novo Nordisk, and Pfizer. Dr. Michos is a co-investigator on a grant funded by Merck, which is paid to her institution.: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); 2023.
  7. Effects of proprotein convertase subtilisin-kexin type 9 inhibitors on inflammatory and hemostatic parameters in post myocardial infarction patients. Eur J Pharmacol 2023:176232 Rehberger Likozar A, Ugovšek S, Šebeštjen M. http://www.ncbi.nlm.nih.gov/pubmed/?term=38070635
  8. Simultaneous acute portal vein thrombosis and ST elevation myocardial infarction in a Covid-19 patient – Case report. Heliyon 2023; 9:e22301 Nournia E, Abbasi H, Bazrafshan M. http://www.ncbi.nlm.nih.gov/pubmed/?term=38074884
  9. Rationale and design of a randomized controlled trial: The effect of intensive lipid-lowering therapy with PCSK9 inhibitor on endothelial-coverage of stent strut after percutaneous coronary intervention (PCI) for patients with acute coronary syndrome (ACS): Optical coherence tomography (OCT) study (PIECES-OCT study). Heliyon 2023; 9:e22222 Yin Z, Li ZF, Zhang WJ et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38045163
  10. Global Burden of Cardiovascular Diseases and Risks, 1990-2022. J Am Coll Cardiol 2023; 82:2350-2473 Mensah GA, Fuster V, Murray CJL, Roth GA. http://www.ncbi.nlm.nih.gov/pubmed/?term=38092509
  11. New Statin Use, Mortality and First Cardiovascular Events in Older US Veterans by Frailty Status. J Am Geriatr Soc 2023; Orkaby AR, Lu B, Ho YL et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38055194
  12. Using machine learning to enhance prediction of atrial fibrillation recurrence after catheter ablation. Journal of arrhythmia 2023; 39:868-875 Brahier MS, Zou F, Abdulkareem M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38045451
  13. Post-COVID-19 vaccination myocarditis: a prospective cohort study pre and post vaccination using cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2023; 25:74 Ng MY, Tam CH, Lee YP et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38057820
  14. Statin pretreatment and cardiac surgery: end of a myth? Journal of cardiovascular medicine (Hagerstown, Md.) 2024; 25:176-177 Oliveri F, Meretta A, Schaerli N et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38149705
  15. Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry. J Clin Lipidol 2023; 17:732-742 Kayıkcioglu M, Başaran Ö, Doğan V et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38072583
  16. Uncertain Benefit of Statins in Pediatric Heart Transplant Recipients: A PHTS Analysis. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2023; Townsend M, Khoury M, Devin Koehl M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38065240
  17. Prevalent Variants in the LDLR Gene Impair Responsiveness to Rosuvastatin among Family Members of Patients with Premature Myocardial Infarction. Journal of personalized medicine 2023; 13 Kien NT, Nghia TT, Hoang NM et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38138952
  18. Long-Term Major Adverse Cardiovascular Events in Patients with Moderate and Severe COVID-19: A Focus on Early Statin Use and Previous CVD. J Tehran Heart Cent 2023; 18:183-195 Khosravi A, Ghodsi S, Memarjafari M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38146416
  19. Real-world effectiveness and safety of evolocumab in very high-risk atherosclerotic cardiovascular disease patients with acute ischemic stroke. Journal of thrombosis and thrombolysis 2023; Zhang T, Zhang Y, Yang Y et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38063944
  20. Evidence-Based Checklist to Delay Cardiac Arrest in Brain-Dead Potential Organ Donors: The DONORS Cluster Randomized Clinical Trial. JAMA network open 2023; 6:e2346901 Westphal GA, Robinson CC, Giordani NE et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38095899
  21. Patients who suffer a first atherosclerotic cardiovascular event while taking statins are often far off of lipid targets. Nutrition, metabolism, and cardiovascular diseases : NMCD 2023; Masana L, Díaz Moya G, Pérez de Isla L. http://www.ncbi.nlm.nih.gov/pubmed/?term=38092606
  22. Effect of renin angiotensin system inhibitors on long-term major cardiovascular outcomes in patients with high atherosclerotic cardiovascular risk. Scientific reports 2023; 13:23066 Wongcharoen W, Osataphan N, Gunaparn S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38155206
  23. Aortic Arch Plaques and the Long-Term Risk of Stroke and Cardiovascular Events in the Statin Era. Stroke 2023; Yoshida Y, Jin Z, Mannina C et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38063018
  24. Major cardiovascular events after COVID-19, event rates post-vaccination, antiviral or anti-inflammatory therapy, and temporal trends: Rationale and methodology of the CORONA-VTE-Network study. Thrombosis research 2023; 232:146-147 Theodorou DJ, Theodorou SJ, Rizos D. http://www.ncbi.nlm.nih.gov/pubmed/?term=37734969
  25. Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review. Yonsei medical journal 2024; 65:19-26 Kang Y, Park JM, Lee SH. http://www.ncbi.nlm.nih.gov/pubmed/?term=38154476
  26. [Study on vaccination in patients with Kawasaki disease]. Zhonghua Er Ke Za Zhi 2023; 61:1148-1151 Xie LP, Liu F, Huang GY. http://www.ncbi.nlm.nih.gov/pubmed/?term=38018056

Endothelium/inflammation

  1. The relationship between plasma cystatin C, mortality and acute respiratory distress syndrome subphenotype in the HARP-2 trial. Crit Care Resusc 2022; 24:251-258 McKelvey MC, Bradbury I, McDowell C et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38046206

Ethnicity

  1. Assessment of ethnic inequalities in diagnostic coding of familial hypercholesterolaemia (FH): A cross-sectional database study in Lambeth, South London. Atherosclerosis 2023; 388:117353 Molokhia M, Wierzbicki AS, Williams H et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38157708
  2. Influence of the rs4238001 Genetic Polymorphism of the SR-B1 Gene on Serum Lipid Levels and Response to Rosuvastatin in Myocardial Infarction Iraqi Patients. Biochemical genetics 2023; Abdulfattah SY, Alagely HS, Samawi FT. http://www.ncbi.nlm.nih.gov/pubmed/?term=38133857
  3. Status of lipid control in Bangladeshi subjects with type 2 diabetes mellitus on lipid-lowering drugs: a multicenter, facility-based, cross-sectional study. BMC endocrine disorders 2023; 23:268 Selim S, Alam MS, Talukder SK et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38053073
  4. Statin use and mortality risk in Asian patients with prostate cancer receiving androgen deprivation therapy: A population-based cohort study. Cancer medicine 2023; Lee YHA, Chan JSK, Hui JMH et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38140773
  5. Risk Factors Amenable to Primary Prevention of Type 2 Diabetes Among Disaggregated Racial and Ethnic Subgroups in the U.S. Diabetes Care 2023; 46:2112-2119 Koyama AK, Bullard KM, Onufrak S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38011520
  6. Effects of Race and Gender Classifications on Atherosclerotic Cardiovascular Disease Risk Estimates for Clinical Decision-Making in a Cohort of Black Transgender Women. Health Equity 2023; 7:803-808 Poteat T, Lett E, Rich AJ et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38076214
  7. Significant Gap Between Guidelines and Practice in the Management of LDL Cholesterol: Insight From the Survey of the Korean Society of Myocardial Infarction. J Korean Med Sci 2023; 38:e419 Lee SY, Cho KH, Lee JH et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38147840
  8. SLCO1B1 functional variants and statin-induced myopathy in people with recent genealogical ancestors from Africa: a population-based real-world study. medRxiv 2023; Yee SW, Haldar T, Kvale M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38076949

FH

  1. Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national study. Am J Prev Cardiol 2024; 17:100611 Nasir K, Mszar R, Cainzos-Achirica M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38125206
  2. Assessment of ethnic inequalities in diagnostic coding of familial hypercholesterolaemia (FH): A cross-sectional database study in Lambeth, South London. Atherosclerosis 2023; 388:117353 Molokhia M, Wierzbicki AS, Williams H et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38157708
  3. Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry. J Clin Lipidol 2023; 17:732-742 Kayıkcioglu M, Başaran Ö, Doğan V et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38072583
  4. Efficacy and Safety of Statin Treatment in Children with Familial Hypercholesterolemia: Outcomes of 20 Years of Experience. Journal of clinical medicine 2023; 12 Motkowski R, Abramowicz P, Kubalska J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38068249

Genetics

  1. Influence of pharmacogenetics on the diversity of response to statins associated with adverse drug reactions. Adv Lab Med 2023; 4:341-352 Sainz de Medrano Sainz JI, Brunet Serra M. http://www.ncbi.nlm.nih.gov/pubmed/?term=38106499
  2. Influence of the rs4238001 Genetic Polymorphism of the SR-B1 Gene on Serum Lipid Levels and Response to Rosuvastatin in Myocardial Infarction Iraqi Patients. Biochemical genetics 2023; Abdulfattah SY, Alagely HS, Samawi FT. http://www.ncbi.nlm.nih.gov/pubmed/?term=38133857
  3. When the same treatment has different response: The role of pharmacogenomics in statin therapy. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2023; 170:115966 Zheng E, Madura P, Grandos J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38061135
  4. Association of HMGCR inhibition with rheumatoid arthritis: a Mendelian randomization and colocalization study. Frontiers in endocrinology 2023; 14:1272167 Ma L, Du Y, Ma C, Liu M. http://www.ncbi.nlm.nih.gov/pubmed/?term=38047111
  5. Computer-Aided, Resistance Gene-Guided Genome Mining for Proteasome and HMG-CoA Reductase Inhibitors. J Ind Microbiol Biotechnol 2023; Jenkinson CB, Podgorny AR, Zhong C, Oakley BR. http://www.ncbi.nlm.nih.gov/pubmed/?term=38061800
  6. Prevalent Variants in the LDLR Gene Impair Responsiveness to Rosuvastatin among Family Members of Patients with Premature Myocardial Infarction. Journal of personalized medicine 2023; 13 Kien NT, Nghia TT, Hoang NM et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38138952
  7. Genetic insights into the association of statin and newer nonstatin drug target genes with human longevity: a Mendelian randomization analysis. Lipids Health Dis 2023; 22:220 Chen H, Zhou X, Hu J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38082436
  8. SLCO1B1 functional variants and statin-induced myopathy in people with recent genealogical ancestors from Africa: a population-based real-world study. medRxiv 2023; Yee SW, Haldar T, Kvale M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38076949
  9. Overview of the year 2023 at Pharmacogenomics. Pharmacogenomics 2023; Jones S. http://www.ncbi.nlm.nih.gov/pubmed/?term=38112072
  10. ASSOCIATION OF SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1 GENE POLYMORPHISM WITH RESPONSE TO ATORVASTATIN AND ASSOCIATED MYOPATHY IN IRAQI DYSLIPIDEMIA PATIENTS. Pol Merkur Lekarski 2023; 51:496-503 Dheyaa Aziz N, Abbood SH, Al-Mayali AH, Hadi NR. http://www.ncbi.nlm.nih.gov/pubmed/?term=38069850

Guidelines

  1. Association of health information technology-driven multidisciplinary approaches with low-density lipoprotein cholesterol target achievement in patients with an acute coronary syndrome. Am J Prev Cardiol 2024; 17:100613 Chen YS, Lin HH, Tsai HY et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38077651
  2. Trends in Primary Prevention Statin Use by Cardiovascular Risk Score From 1999 to 2018: A Repeated Cross-Sectional Study. Annals of internal medicine 2023; Kim CJ, Sussman JB, Mukamal KJ et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38048586
  3. Recommendations for the primary prevention of atherosclerotic cardiovascular disease in primary care: study protocol for a systematic guideline review. BMJ Open 2023; 13:e074788 Schürmann L, Bredehorst M, González-González AI et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38070923
  4. Global Burden of Cardiovascular Diseases and Risks, 1990-2022. J Am Coll Cardiol 2023; 82:2350-2473 Mensah GA, Fuster V, Murray CJL, Roth GA. http://www.ncbi.nlm.nih.gov/pubmed/?term=38092509
  5. Significant Gap Between Guidelines and Practice in the Management of LDL Cholesterol: Insight From the Survey of the Korean Society of Myocardial Infarction. J Korean Med Sci 2023; 38:e419 Lee SY, Cho KH, Lee JH et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38147840

LDL – related parameters

  1. Association of health information technology-driven multidisciplinary approaches with low-density lipoprotein cholesterol target achievement in patients with an acute coronary syndrome. Am J Prev Cardiol 2024; 17:100613 Chen YS, Lin HH, Tsai HY et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38077651
  2. Status of lipid control in Bangladeshi subjects with type 2 diabetes mellitus on lipid-lowering drugs: a multicenter, facility-based, cross-sectional study. BMC endocrine disorders 2023; 23:268 Selim S, Alam MS, Talukder SK et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38053073
  3. The antihyperlipidemic effect of a combined supplement of standardized dry extracts of amla (Emblica officinalis), walnut (Juglans regia), olive (Olea europaea) and red yeast rice (Monascus purpureus) powder: Reduction in circulatory low-density lipoprotein-cholesterol (LDL-C) and remnant cholesterol (RC) levels in patients with hypercholesterolemia. Frontiers in pharmacology 2023; 14:1280234 Hermans MP, Dierckxsens Y, Janssens I et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38089061
  4. Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry. J Clin Lipidol 2023; 17:732-742 Kayıkcioglu M, Başaran Ö, Doğan V et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38072583
  5. Evolution of More Aggressive LDL-Cholesterol Targets and Therapies for Cardiovascular Disease Prevention. Journal of clinical medicine 2023; 12 Jones JE, Tang KS, Barseghian A, Wong ND. http://www.ncbi.nlm.nih.gov/pubmed/?term=38068483
  6. Comparison of the efficacy and safety of Shanhuang Jiangzhi tablets and atorvastatin in the treatment of patients with hyperlipidaemia. J Health Popul Nutr 2023; 42:143 Sun G, Liang X. http://www.ncbi.nlm.nih.gov/pubmed/?term=38098069
  7. Significant Gap Between Guidelines and Practice in the Management of LDL Cholesterol: Insight From the Survey of the Korean Society of Myocardial Infarction. J Korean Med Sci 2023; 38:e419 Lee SY, Cho KH, Lee JH et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38147840
  8. Patients who suffer a first atherosclerotic cardiovascular event while taking statins are often far off of lipid targets. Nutrition, metabolism, and cardiovascular diseases : NMCD 2023; Masana L, Díaz Moya G, Pérez de Isla L. http://www.ncbi.nlm.nih.gov/pubmed/?term=38092606
  9. Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review. Yonsei medical journal 2024; 65:19-26 Kang Y, Park JM, Lee SH. http://www.ncbi.nlm.nih.gov/pubmed/?term=38154476

Lifestyle

  1. Make My Day: primary prevention of stroke using engaging everyday activities as a mediator of sustainable health – a randomised controlled trial and process evaluation protocol. BMJ Open 2023; 13:e072037 Patomella AH, Guidetti S, Hagströmer M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38056945
  2. The antihyperlipidemic effect of a combined supplement of standardized dry extracts of amla (Emblica officinalis), walnut (Juglans regia), olive (Olea europaea) and red yeast rice (Monascus purpureus) powder: Reduction in circulatory low-density lipoprotein-cholesterol (LDL-C) and remnant cholesterol (RC) levels in patients with hypercholesterolemia. Frontiers in pharmacology 2023; 14:1280234 Hermans MP, Dierckxsens Y, Janssens I et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38089061
  3. Comparison of the efficacy and safety of Shanhuang Jiangzhi tablets and atorvastatin in the treatment of patients with hyperlipidaemia. J Health Popul Nutr 2023; 42:143 Sun G, Liang X. http://www.ncbi.nlm.nih.gov/pubmed/?term=38098069
  4. Effect of Berberine on Pharmacokinetics and Pharmacodynamics of Atorvastatin in Hyperlipidemia Rats. Xenobiotica 2023:1-27 Wu F, Cui M, Wang S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38054840

Meta-analyses

  1. The role of pravastatin in preventing preeclampsia in high-risk pregnant women: a meta-analysis with trial sequential analysis. Am J Obstet Gynecol MFM 2023:101260 Provinciatto H, Barbalho ME, Almeida J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38109997
  2. Ezetimibe and atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Frontiers in cardiovascular medicine 2023; 10:1269172 Omidi F, Rahmannia M, Shahidi Bonjar AH et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38075958
  3. Efficacy of Topical Cholesterol and Statin Combination Therapy in the Treatment of Porokeratosis: A Systematic Review and Meta-Analysis. J Drugs Dermatol 2023; 22:1160-1165 Casale F, Walters N, Peach A, Dong J. http://www.ncbi.nlm.nih.gov/pubmed/?term=38051843
  4. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis. PLoS One 2023; 18:e0295359 Imran TF, Khan AA, Has P et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38055686
  5. Intolerance upon statin rechallenge: A systematic review and meta-analysis of randomized controlled trials. PLoS One 2023; 18:e0295857 Kraut R, Wierenga F, Molstad E et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38128013
  6. Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review. Yonsei medical journal 2024; 65:19-26 Kang Y, Park JM, Lee SH. http://www.ncbi.nlm.nih.gov/pubmed/?term=38154476

Metabolic Syndrome – Diabetes

  1. The role of pravastatin in preventing preeclampsia in high-risk pregnant women: a meta-analysis with trial sequential analysis. Am J Obstet Gynecol MFM 2023:101260 Provinciatto H, Barbalho ME, Almeida J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38109997
  2. Ezetimibe and atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Frontiers in cardiovascular medicine 2023; 10:1269172 Omidi F, Rahmannia M, Shahidi Bonjar AH et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38075958
  3. Efficacy of Topical Cholesterol and Statin Combination Therapy in the Treatment of Porokeratosis: A Systematic Review and Meta-Analysis. J Drugs Dermatol 2023; 22:1160-1165 Casale F, Walters N, Peach A, Dong J. http://www.ncbi.nlm.nih.gov/pubmed/?term=38051843
  4. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis. PLoS One 2023; 18:e0295359 Imran TF, Khan AA, Has P et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38055686
  5. Intolerance upon statin rechallenge: A systematic review and meta-analysis of randomized controlled trials. PLoS One 2023; 18:e0295857 Kraut R, Wierenga F, Molstad E et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38128013
  6. Moderate-Intensity Rosuvastatin/Ezetimibe Combination versus Quadruple-Dose Rosuvastatin Monotherapy: A Meta-Analysis and Systemic Review. Yonsei medical journal 2024; 65:19-26 Kang Y, Park JM, Lee SH. http://www.ncbi.nlm.nih.gov/pubmed/?term=38154476

New treatments

  1. Development of a Microminipig Model of Atherosclerosis for the Evaluation of a HMGCR Inhibitor. In Vivo 2024; 38:98-106 Yamada T, Kawaguchi H, Matsuoka A et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38148058
  2. Identification of 4-amino-2-Pyridones as new potent PCSK9 inhibitors: From phenotypic hit discovery to in vivo tolerability. European journal of medicinal chemistry 2023; 265:116063 Giannessi L, Lupo MG, Rossi I et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38160616
  3. Getting a CLEARER Picture: Bempedoic Acid and Cardiovascular Outcomes in Patients with Statin Intolerance. Southern medical journal 2024; 117:23-24 Campbell LA, Ammon JP, Jackson CD. http://www.ncbi.nlm.nih.gov/pubmed/?term=38151247
  4. Targeted Degradation of PCSK9 In Vivo by Autophagy-Tethering Compounds. Journal of medicinal chemistry 2023; Ouyang Z, Ma M, Zhang Z et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38112492
  5. Bempedoic acid: new evidence and recommendations on use. Curr Opin Lipidol 2024; 35:41-50 Paponja K, Pećin I, Reiner Ž, Banach M. http://www.ncbi.nlm.nih.gov/pubmed/?term=38085172
  6. Bempedoic acid: a new player for statin-intolerant patients and beyond. Current opinion in endocrinology, diabetes, and obesity 2023; Giordano S, Spaccarotella CAM, Esposito G, Indolfi C. http://www.ncbi.nlm.nih.gov/pubmed/?term=38095480
  7. Real-world effectiveness and safety of evolocumab in very high-risk atherosclerotic cardiovascular disease patients with acute ischemic stroke. Journal of thrombosis and thrombolysis 2023; Zhang T, Zhang Y, Yang Y et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38063944
  8. Rationale and design of a randomized controlled trial: The effect of intensive lipid-lowering therapy with PCSK9 inhibitor on endothelial-coverage of stent strut after percutaneous coronary intervention (PCI) for patients with acute coronary syndrome (ACS): Optical coherence tomography (OCT) study (PIECES-OCT study). Heliyon 2023; 9:e22222 Yin Z, Li ZF, Zhang WJ et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38045163
  9. Discovery of Natural Potent HMG-CoA Reductase Degraders for Lowering Cholesterol. Angew Chem Int Ed Engl 2023:e202313859 Su XZ, Zhang LF, Hu K et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38055195
  10. Effect of statins combined with PCSK9 inhibitors on the prognosis of patients with acute coronary syndromes after interventional therapy. Cell Mol Biol (Noisy-le-grand) 2023; 69:262-267 Shi L, Ye Z, Gu Q, Li Y. http://www.ncbi.nlm.nih.gov/pubmed/?term=38063128
  11. Effects of proprotein convertase subtilisin-kexin type 9 inhibitors on inflammatory and hemostatic parameters in post myocardial infarction patients. Eur J Pharmacol 2023:176232 Rehberger Likozar A, Ugovšek S, Šebeštjen M. http://www.ncbi.nlm.nih.gov/pubmed/?term=38070635
  12. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. The lancet. Diabetes & endocrinology 2023; Ray KK, Nicholls SJ, Li N et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38061370
  13. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis. PLoS One 2023; 18:e0295359 Imran TF, Khan AA, Has P et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38055686

Other

  1. Long-Term Major Adverse Cardiovascular Events in Patients with Moderate and Severe COVID-19: A Focus on Early Statin Use and Previous CVD. J Tehran Heart Cent 2023; 18:183-195 Khosravi A, Ghodsi S, Memarjafari M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38146416
  2. Pitavastatin for cardiovascular health in patients with HIV infection. Aids 2024; 38:271 Sbrana F, Dal Pino B. http://www.ncbi.nlm.nih.gov/pubmed/?term=38116725
  3. Differential effect of atorvastatin and pravastatin on thoracic spine attenuation: A sub-analysis of a randomized clinical trial. Atherosclerosis 2023; 388:117425 Raggi P, Takyar FM, Gadiyaram V et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38109819
  4. Effect of statins on hearing outcome in patients with idiopathic sudden sensorineural hearing loss. Laryngoscope Investig Otolaryngol 2023; 8:1631-1636 Nitta Y, Kurioka T, Furuki S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38130250
  5. Influence of a Short Course of Ritonavir Used as Booster in Antiviral Therapies Against SARS-CoV-2 on the Exposure of Atorvastatin and Rosuvastatin. Cardiovasc Drugs Ther 2023; Krohmer E, Rohr BS, Stoll F et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38112932
  6. Pravastatin promotes type 2 diabetes vascular calcification through activating intestinal Bacteroides fragilis to induce macrophage M1 polarization. Journal of diabetes 2023; Chen C, Liang ZF, He YQ et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38112268
  7. Evidence-Based Checklist to Delay Cardiac Arrest in Brain-Dead Potential Organ Donors: The DONORS Cluster Randomized Clinical Trial. JAMA network open 2023; 6:e2346901 Westphal GA, Robinson CC, Giordani NE et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38095899
  8. Simultaneous acute portal vein thrombosis and ST elevation myocardial infarction in a Covid-19 patient – Case report. Heliyon 2023; 9:e22301 Nournia E, Abbasi H, Bazrafshan M. http://www.ncbi.nlm.nih.gov/pubmed/?term=38074884
  9. Effect of statin treatment on metabolites, lipids and prostanoids in patients with Statin Associated Muscle Symptoms (SAMS). PLoS One 2023; 18:e0294498 Garrett TJ, Puchowicz MA, Park EA et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38100464
  10. [Study on vaccination in patients with Kawasaki disease]. Zhonghua Er Ke Za Zhi 2023; 61:1148-1151 Xie LP, Liu F, Huang GY. http://www.ncbi.nlm.nih.gov/pubmed/?term=38018056
  11. Uncertain Benefit of Statins in Pediatric Heart Transplant Recipients: A PHTS Analysis. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2023; Townsend M, Khoury M, Devin Koehl M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38065240
  12. An update on combination therapies for multiple sclerosis: where are we now? Expert Rev Neurother 2023:1-15 Sorensen PS, Magyari M, Sellebjerg F. http://www.ncbi.nlm.nih.gov/pubmed/?term=38058171
  13. Prasun P, Ganesh J. Lathosterolosis. In: GeneReviews(®). Edited by: Adam MP, Feldman J, Mirzaa GM et al. Seattle (WA): University of Washington, Seattle
  14. Copyright © 1993-2023, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.; 1993.
  15. Cardiovascular Events After Coronavirus Disease 2019 Vaccinations Versus Long Coronavirus Disease. Anatol J Cardiol 2023; 27:735-736 Jargin SV. http://www.ncbi.nlm.nih.gov/pubmed/?term=37842757
  16. Efficacy of Topical Cholesterol and Statin Combination Therapy in the Treatment of Porokeratosis: A Systematic Review and Meta-Analysis. J Drugs Dermatol 2023; 22:1160-1165 Casale F, Walters N, Peach A, Dong J. http://www.ncbi.nlm.nih.gov/pubmed/?term=38051843
  17. Impact of influenza, herpes zoster, and pneumococcal vaccinations on the incidence of cardiovascular events in subjects aged over 65 years: a systematic review. Geroscience 2023; 45:3419-3447 Addario A, Célarier T, Bongue B et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=37269492
  18. Major cardiovascular events after COVID-19, event rates post-vaccination, antiviral or anti-inflammatory therapy, and temporal trends: Rationale and methodology of the CORONA-VTE-Network study. Thrombosis research 2023; 232:146-147 Theodorou DJ, Theodorou SJ, Rizos D. http://www.ncbi.nlm.nih.gov/pubmed/?term=37734969
  19. Post-COVID-19 vaccination myocarditis: a prospective cohort study pre and post vaccination using cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2023; 25:74 Ng MY, Tam CH, Lee YP et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38057820
  20. Rate and Cause of Sudden Cardiac Death in the Young During the COVID-19 Pandemic and Vaccination. Circulation 2023; 148:2069-2071 De Gaspari M, Fedeli U, Saia M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38109343

Pleiotropic effects of statins

  1. Metabolic changes with the occurrence of atherosclerotic plaques and the effects of statins. Frontiers in immunology 2023; 14:1301051 Zhao L, Ma D, Wang L et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38143759
  2. Simvastatin Enhances the Radiosensitivity of Androgen-independent Prostate Cancer Cells via Inhibition of RAD51 Expression. Anticancer research 2024; 44:93-98 Oka D, Sekine Y, Tsuji Y et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38159995
  3. Effect of preoperative moderate-dose statin and duration on acute kidney injury after cardiac surgery: a retrospective cohort study. Current medical research and opinion 2023:1-10 Jiang J, Liu X, Cheng Z et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38146934
  4. Statin treatment remodels the HDL subclass lipidome and proteome in hypertriglyceridemia. Journal of lipid research 2023:100494 Chapman MJ, Orsoni A, Mellett NA et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38160756
  5. A Prospective Study of the Effect and Safety of Atorvastatin on the Recurrence of Chronic Subdural Hematoma after Burr Hole Surgery. Asian J Neurosurg 2023; 18:567-572 Bumpetch D, Sitthinamsuwan B, Nunta-Aree S. http://www.ncbi.nlm.nih.gov/pubmed/?term=38152511
  6. Effect of bisphosphonates and statins on the in vitro radiosensitivity of breast cancer cell lines. Pharmacological reports : PR 2023; Bodgi L, Bou-Gharios J, Azzi J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38151641
  7. Atorvastatin as an Antihypertensive Agent: A Pilot Study. Cureus 2023; 15:e49532 Ali N, Faheem M, Ullah H et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38156151
  8. 3D printed polylactic acid-based nanocomposite scaffold stuffed with microporous simvastatin-loaded polyelectrolyte for craniofacial reconstruction. International journal of biological macromolecules 2023; 258:128917 Tavakoli M, Salehi H, Emadi R et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38134992
  9. Effect of three-day atorvastatin administration on coagulation factors in patients with prior venous thromboembolism and healthy subjects. A preliminary study. Journal of cardiovascular pharmacology 2023; Stępień K, Żółciński M, Ząbczyk M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38117119
  10. Combined quercetin and simvastatin attenuate hepatic fibrosis in rats by modulating SphK1/NLRP3 pathways. Life sciences 2023:122349 Salama YA, Hassan HM, El-Gayar AM, Abdel-Rahman N. http://www.ncbi.nlm.nih.gov/pubmed/?term=38128755
  11. Differential effect of atorvastatin and pravastatin on thoracic spine attenuation: A sub-analysis of a randomized clinical trial. Atherosclerosis 2023; 388:117425 Raggi P, Takyar FM, Gadiyaram V et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38109819
  12. Atorvastatin exerts dual effects of lesion regression and ovarian protection in the prevention and treatment of endometriosis. Eur J Pharmacol 2023:176261 Qin X, Wang Q, Xu D et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38141938
  13. The role of pravastatin in preventing preeclampsia in high-risk pregnant women: a meta-analysis with trial sequential analysis. Am J Obstet Gynecol MFM 2023:101260 Provinciatto H, Barbalho ME, Almeida J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38109997
  14. The Blocking of Drug Resistance Channels by Selected Hydrophobic Statins in Chemoresistance Human Melanoma. Biomolecules 2023; 13 Placha W, Suder P, Panek A et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38136555
  15. Statins and cognitive decline in patients with Alzheimer's and mixed dementia: a longitudinal registry-based cohort study. Alzheimer's research & therapy 2023; 15:220 Petek B, Häbel H, Xu H et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38115091
  16. Statin therapy and outcome in Takotsubo syndrome patients: Results from the multicenter international GEIST registry. Atherosclerosis 2023; 389:117421 Novo G, Arcari L, Stiermaier T et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38134646
  17. Effect of statins on hearing outcome in patients with idiopathic sudden sensorineural hearing loss. Laryngoscope Investig Otolaryngol 2023; 8:1631-1636 Nitta Y, Kurioka T, Furuki S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38130250
  18. Statin use reduces radiation-induced stroke risk in advanced nasopharyngeal carcinoma patients. Radiother Oncol 2023; 191:110067 Lin CY, Chang CL, Lin KC et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38142934
  19. Abnormal Cholesterol Metabolism and Lysosomal Dysfunction Induce Age-Related Hearing Loss by Inhibiting mTORC1-TFEB-Dependent Autophagy. Int J Mol Sci 2023; 24 Lee YY, Ha J, Kim YS et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38139347
  20. Statin use and mortality risk in Asian patients with prostate cancer receiving androgen deprivation therapy: A population-based cohort study. Cancer medicine 2023; Lee YHA, Chan JSK, Hui JMH et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38140773
  21. Influence of a Short Course of Ritonavir Used as Booster in Antiviral Therapies Against SARS-CoV-2 on the Exposure of Atorvastatin and Rosuvastatin. Cardiovasc Drugs Ther 2023; Krohmer E, Rohr BS, Stoll F et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38112932
  22. Targeting the CCL2-CCR2 signaling pathway: potential implications of statins beyond cardiovascular diseases. The Journal of pharmacy and pharmacology 2023; Gholamalizadeh H, Ensan B, Sukhorukov VN, Sahebkar A. http://www.ncbi.nlm.nih.gov/pubmed/?term=38127312
  23. Lipophilic Statins Eliminate Senescent Endothelial Cells by inducing Anoikis-Related Cell Death. Cells 2023; 12 Belakova B, Wedige NK, Awad EM et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38132158
  24. Erratum to atorvastatin inhibits pancreatic cancer cells proliferation and invasion likely by suppressing neurotrophin receptor signaling. Transl Cancer Res 2023; 12:3220-3221. http://www.ncbi.nlm.nih.gov/pubmed/?term=38130299
  25. Inhibiting cholesterol de novo synthesis promotes hepatocellular carcinoma progression by upregulating prostaglandin E synthase 2-mediated arachidonic acid metabolism under high fatty acid conditions. Cancer science 2023; Zhao Z, Liu X, Xiang Y et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38081591
  26. High-throughput target trial emulation for Alzheimer's disease drug repurposing with real-world data. Nature communications 2023; 14:8180 Zang C, Zhang H, Xu J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38081829
  27. Evidence-Based Checklist to Delay Cardiac Arrest in Brain-Dead Potential Organ Donors: The DONORS Cluster Randomized Clinical Trial. JAMA network open 2023; 6:e2346901 Westphal GA, Robinson CC, Giordani NE et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38095899
  28. Role of individual and combined impact of simvastatin and α-TCP in rat calvarial bone defect: An experimental study. Saudi Dent J 2023; 35:861-868 Sugumaran S, Selvam D, Nivedhitha MS et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38077229
  29. The evaluation of atorvastatin as an adjunct to fluconazole for the anti-fungal prophylaxis in acute myeloid leukemia: a multicenter, triple-blinded, randomized clinical trial. Naunyn-Schmiedeberg's archives of pharmacology 2023; Saber-Moghaddam N, Nodeh MM, Ghavami V et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38095652
  30. Effect of systemic atorvastatin on bone regeneration in critical-sized defects in hyperlipidemia: an experimental study. International journal of implant dentistry 2023; 9:50 Öztürk K, Kuzu TE, Ayrıkçil S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38097856
  31. Low-Density Lipoprotein Cholesterol and Statin Usage Are Associated With Rates of Pseudarthrosis Following Single-Level Posterior Lumbar Interbody Fusion. Spine 2023; Lavu MS, Eghrari NB, Makineni PS et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38073195
  32. Letter: Statin use in patients with type 2 diabetes has lower risk of hip fractures. Diabetes/metabolism research and reviews 2023:e3756 Huang SW, Jou IM, Chang R. http://www.ncbi.nlm.nih.gov/pubmed/?term=38093549
  33. Impact of atorvastatin and mesenchymal stem cells combined with ivermectin on murine trichinellosis. Parasitol Res 2023; 123:57 Hassan ZR, El-Sayed S, Zekry KM et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38105357
  34. Enhanced Neuroprotective Synergy of Atorvastatin and Magnesium L-Threonate in a Rat Model of Alzheimer's Disease Induced by Aluminum Chloride. Cureus 2023; 15:e48400 Gangoda DM, Saiyed MS, Pathan SR et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38074017
  35. Statin Use and the Risk of Venous Thromboembolism in Women Taking Hormone Therapy. JAMA network open 2023; 6:e2348213 Davis JW, Weller SC, Porterfield L et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38100102
  36. Genetic insights into the association of statin and newer nonstatin drug target genes with human longevity: a Mendelian randomization analysis. Lipids Health Dis 2023; 22:220 Chen H, Zhou X, Hu J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38082436
  37. Retracted: Simvastatin in the Treatment of Colorectal Cancer: A Review. Evidence-based complementary and alternative medicine : eCAM 2023; 2023:9767203 And Alternative Medicine EC. http://www.ncbi.nlm.nih.gov/pubmed/?term=38093875
  38. Current Research on the Influence of Statin Treatment on Rotator Cuff Healing. Clin Orthop Surg 2023; 15:873-879 Yoon JP, Park SJ, Kim DH et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38045588
  39. Rationale and design of a randomized controlled trial: The effect of intensive lipid-lowering therapy with PCSK9 inhibitor on endothelial-coverage of stent strut after percutaneous coronary intervention (PCI) for patients with acute coronary syndrome (ACS): Optical coherence tomography (OCT) study (PIECES-OCT study). Heliyon 2023; 9:e22222 Yin Z, Li ZF, Zhang WJ et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38045163
  40. Association between statin use on delirium and 30-day mortality in patients with chronic obstructive pulmonary disease in the intensive care unit. European journal of medical research 2023; 28:572 Xia J, Hu C, Wang L, Zhang Y. http://www.ncbi.nlm.nih.gov/pubmed/?term=38062497
  41. The relationship between statin administration timing and survival outcomes in patients with cancer receiving immune checkpoint blockade. J Chemother 2023:1-6 Wang Z, See XY, Chiang CH et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38062978
  42. An update on combination therapies for multiple sclerosis: where are we now? Expert Rev Neurother 2023:1-15 Sorensen PS, Magyari M, Sellebjerg F. http://www.ncbi.nlm.nih.gov/pubmed/?term=38058171
  43. Statins Effects on Blood Clotting: A Review. Cells 2023; 12 Siniscalchi C, Basaglia M, Riva M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38067146
  44. Statin use moderates APOE's and CRP's associations with dementia and is associated with lesser dementia severity in ε4 carriers. Alzheimer's & dementia : the journal of the Alzheimer's Association 2023; Royall DR, Palmer RF. http://www.ncbi.nlm.nih.gov/pubmed/?term=38055626
  45. Effects of proprotein convertase subtilisin-kexin type 9 inhibitors on inflammatory and hemostatic parameters in post myocardial infarction patients. Eur J Pharmacol 2023:176232 Rehberger Likozar A, Ugovšek S, Šebeštjen M. http://www.ncbi.nlm.nih.gov/pubmed/?term=38070635
  46. The relationship between plasma cystatin C, mortality and acute respiratory distress syndrome subphenotype in the HARP-2 trial. Crit Care Resusc 2022; 24:251-258 McKelvey MC, Bradbury I, McDowell C et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38046206
  47. Statins in Graves Orbitopathy: A New Therapeutic Tool. Ophthalmic plastic and reconstructive surgery 2023; 39:S29-s39 Lanzolla G, Comi S, Cosentino G et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38054983
  48. Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial. Hepatol Commun 2023; 7 Kronborg TM, Schierwagen R, Trošt K et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38051553
  49. Simvastatin/hydrogel-loaded 3D-printed titanium alloy scaffolds suppress osteosarcoma via TF/NOX2-associated ferroptosis while repairing bone defects. Bioact Mater 2024; 33:223-241 Jing Z, Yuan W, Wang J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38045570
  50. Lovastatin Treatment Inducing Apoptosis in Human Pancreatic Cancer Cells by Inhibiting Cholesterol Rafts in Plasma Membrane and Mitochondria. Int J Mol Sci 2023; 24 Gyoten M, Luo Y, Fujiwara-Tani R et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38069135
  51. Atorvastatin mitigates memory deficits and brain monocyte infiltration in chronic hypercholesterolemia. Aging 2023; 15 Gong F, Shi Q, Mou X et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38048213
  52. Enhanced therapeutic efficacy of doxorubicin/cyclophosphamide in combination with pitavastatin or simvastatin against breast cancer cells. Medical oncology (Northwood, London, England) 2023; 41:7 Dewidar SA, Hamdy O, Soliman MM et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38051378
  53. Efficacy of Topical Cholesterol and Statin Combination Therapy in the Treatment of Porokeratosis: A Systematic Review and Meta-Analysis. J Drugs Dermatol 2023; 22:1160-1165 Casale F, Walters N, Peach A, Dong J. http://www.ncbi.nlm.nih.gov/pubmed/?term=38051843
  54. Using machine learning to enhance prediction of atrial fibrillation recurrence after catheter ablation. Journal of arrhythmia 2023; 39:868-875 Brahier MS, Zou F, Abdulkareem M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38045451
  55. Simvastatin restores pulmonary endothelial function in the setting of pulmonary over-circulation. Nitric Oxide 2023; 142:58-68 Boehme JT, Sun X, Lu Q et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38061411
  56. Simvastatin Differentially Modulates Glial Functions in Cultured Cortical and Hypothalamic Astrocytes Derived from Interferon α/β Receptor Knockout mice. Neurochemical research 2023; Bobermin LD, Sesterheim P, da Costa DS et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38063948
  57. Hydrogels Loaded with Atorvastatin-Metal Organic Framework Have a Preventive Effect on Coronary Heart Disease. Chem Biodivers 2023:e202301511 Bai X, Jiang J, Tu S, Zhang W. http://www.ncbi.nlm.nih.gov/pubmed/?term=38063816
  58. Inhibitors of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Decrease the Growth, Ergosterol Synthesis and Generation of petite Mutants in Candida glabrata and Candida albicans. Int J Mol Sci 2023; 24 Andrade-Pavón D, Sánchez-Sandoval E, Tamariz J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38069194
  59. Recommendations for the primary prevention of atherosclerotic cardiovascular disease in primary care: study protocol for a systematic guideline review. BMJ Open 2023; 13:e074788 Schürmann L, Bredehorst M, González-González AI et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38070923

Primary prevention

  1. Association of low-dose aspirin use for primary prevention with self-reported kidney stones prevalence: a cross-sectional study. World J Urol 2023; 41:3753-3758 Yang M, Li Y, Chen Y, Huang F. http://www.ncbi.nlm.nih.gov/pubmed/?term=37838641
  2. Make My Day: primary prevention of stroke using engaging everyday activities as a mediator of sustainable health – a randomised controlled trial and process evaluation protocol. BMJ Open 2023; 13:e072037 Patomella AH, Guidetti S, Hagströmer M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38056945
  3. Risk Factors Amenable to Primary Prevention of Type 2 Diabetes Among Disaggregated Racial and Ethnic Subgroups in the U.S. Diabetes Care 2023; 46:2112-2119 Koyama AK, Bullard KM, Onufrak S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38011520
  4. Trends in Primary Prevention Statin Use by Cardiovascular Risk Score From 1999 to 2018: A Repeated Cross-Sectional Study. Annals of internal medicine 2023; Kim CJ, Sussman JB, Mukamal KJ et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38048586
  5. Evolution of More Aggressive LDL-Cholesterol Targets and Therapies for Cardiovascular Disease Prevention. Journal of clinical medicine 2023; 12 Jones JE, Tang KS, Barseghian A, Wong ND. http://www.ncbi.nlm.nih.gov/pubmed/?term=38068483
  6. Recommendations for the primary prevention of atherosclerotic cardiovascular disease in primary care: study protocol for a systematic guideline review. BMJ Open 2023; 13:e074788 Schürmann L, Bredehorst M, González-González AI et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38070923
  7. Aspirin use for primary prevention in older adults. J Am Geriatr Soc 2023; 71:3927-3929 Luepker RV, Van't Hof JR, Eder M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=37596891
  8. Trends in Upper Gastrointestinal Bleeding in Patients on Primary Prevention Aspirin: A Nationwide Emergency Department Sample Analysis, 2016-2020. Am J Med 2023; 136:1179-1186.e1171 Li DK, Laine L, Shung DL. http://www.ncbi.nlm.nih.gov/pubmed/?term=37696350
  9. Rate and Cause of Sudden Cardiac Death in the Young During the COVID-19 Pandemic and Vaccination. Circulation 2023; 148:2069-2071 De Gaspari M, Fedeli U, Saia M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38109343
  10. Primary prevention implantable cardioverter defibrillators for patients with heart failure. Heart 2023; 110:65-73 Beggs SAS, Wright GA, Gardner RS. http://www.ncbi.nlm.nih.gov/pubmed/?term=37463731

Registry data

  1. Effect of preoperative moderate-dose statin and duration on acute kidney injury after cardiac surgery: a retrospective cohort study. Current medical research and opinion 2023:1-10 Jiang J, Liu X, Cheng Z et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38146934
  2. Statins and cognitive decline in patients with Alzheimer's and mixed dementia: a longitudinal registry-based cohort study. Alzheimer's research & therapy 2023; 15:220 Petek B, Häbel H, Xu H et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38115091
  3. Statin therapy and outcome in Takotsubo syndrome patients: Results from the multicenter international GEIST registry. Atherosclerosis 2023; 389:117421 Novo G, Arcari L, Stiermaier T et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38134646
  4. Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national study. Am J Prev Cardiol 2024; 17:100611 Nasir K, Mszar R, Cainzos-Achirica M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38125206
  5. Statin use reduces radiation-induced stroke risk in advanced nasopharyngeal carcinoma patients. Radiother Oncol 2023; 191:110067 Lin CY, Chang CL, Lin KC et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38142934
  6. Statin use and mortality risk in Asian patients with prostate cancer receiving androgen deprivation therapy: A population-based cohort study. Cancer medicine 2023; Lee YHA, Chan JSK, Hui JMH et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38140773
  7. Association between statin use on delirium and 30-day mortality in patients with chronic obstructive pulmonary disease in the intensive care unit. European journal of medical research 2023; 28:572 Xia J, Hu C, Wang L, Zhang Y. http://www.ncbi.nlm.nih.gov/pubmed/?term=38062497
  8. Status of lipid control in Bangladeshi subjects with type 2 diabetes mellitus on lipid-lowering drugs: a multicenter, facility-based, cross-sectional study. BMC endocrine disorders 2023; 23:268 Selim S, Alam MS, Talukder SK et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38053073
  9. Statin use moderates APOE's and CRP's associations with dementia and is associated with lesser dementia severity in ε4 carriers. Alzheimer's & dementia : the journal of the Alzheimer's Association 2023; Royall DR, Palmer RF. http://www.ncbi.nlm.nih.gov/pubmed/?term=38055626
  10. New Statin Use, Mortality and First Cardiovascular Events in Older US Veterans by Frailty Status. J Am Geriatr Soc 2023; Orkaby AR, Lu B, Ho YL et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38055194
  11. Trends in Primary Prevention Statin Use by Cardiovascular Risk Score From 1999 to 2018: A Repeated Cross-Sectional Study. Annals of internal medicine 2023; Kim CJ, Sussman JB, Mukamal KJ et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38048586
  12. Misperceptions and management of LDL-cholesterol in secondary prevention of patients with familial hypercholesterolemia in cardiology practice: Real-life evidence from the EPHESUS registry. J Clin Lipidol 2023; 17:732-742 Kayıkcioglu M, Başaran Ö, Doğan V et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38072583
  13. ASSOCIATION OF SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1 GENE POLYMORPHISM WITH RESPONSE TO ATORVASTATIN AND ASSOCIATED MYOPATHY IN IRAQI DYSLIPIDEMIA PATIENTS. Pol Merkur Lekarski 2023; 51:496-503 Dheyaa Aziz N, Abbood SH, Al-Mayali AH, Hadi NR. http://www.ncbi.nlm.nih.gov/pubmed/?term=38069850
  14. Trends in Upper Gastrointestinal Bleeding in Patients on Primary Prevention Aspirin: A Nationwide Emergency Department Sample Analysis, 2016-2020. Am J Med 2023; 136:1179-1186.e1171 Li DK, Laine L, Shung DL. http://www.ncbi.nlm.nih.gov/pubmed/?term=37696350

Renal disease

  1. Effect of preoperative moderate-dose statin and duration on acute kidney injury after cardiac surgery: a retrospective cohort study. Current medical research and opinion 2023:1-10 Jiang J, Liu X, Cheng Z et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38146934
  2. Statin therapy in patients with early-stage autosomal dominant polycystic kidney disease: Design and baseline characteristics. Contemporary clinical trials 2023:107423 Gitomer BY, Wang W, George D et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38151173
  3. Association of low-dose aspirin use for primary prevention with self-reported kidney stones prevalence: a cross-sectional study. World J Urol 2023; 41:3753-3758 Yang M, Li Y, Chen Y, Huang F. http://www.ncbi.nlm.nih.gov/pubmed/?term=37838641
  4. The relationship between plasma cystatin C, mortality and acute respiratory distress syndrome subphenotype in the HARP-2 trial. Crit Care Resusc 2022; 24:251-258 McKelvey MC, Bradbury I, McDowell C et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38046206
  5. Advances in the management of chronic kidney disease. Bmj 2023; 383:e074216Chen TK, Hoenig MP, Nitsch D, Grams ME. http://www.ncbi.nlm.nih.gov/pubmed/?term=38052474
  6. Statins, Mortality, and Major Adverse Cardiovascular Events Among US Veterans With Chronic Kidney Disease. JAMA network open 2023; 6:e2346373 Barayev O, Hawley CE, Wellman H et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38055276

Safety and side effects

  1. Changes in Gut Microbiota After Statin Administration: A New Candidate Mechanism for Statin-Associated New-Onset Type 2 Diabetes. Arterioscler Thromb Vasc Biol 2023; Sakuma I. http://www.ncbi.nlm.nih.gov/pubmed/?term=38152889
  2. Effect of preoperative moderate-dose statin and duration on acute kidney injury after cardiac surgery: a retrospective cohort study. Current medical research and opinion 2023:1-10 Jiang J, Liu X, Cheng Z et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38146934
  3. Getting a CLEARER Picture: Bempedoic Acid and Cardiovascular Outcomes in Patients with Statin Intolerance. Southern medical journal 2024; 117:23-24 Campbell LA, Ammon JP, Jackson CD. http://www.ncbi.nlm.nih.gov/pubmed/?term=38151247
  4. A Prospective Study of the Effect and Safety of Atorvastatin on the Recurrence of Chronic Subdural Hematoma after Burr Hole Surgery. Asian J Neurosurg 2023; 18:567-572 Bumpetch D, Sitthinamsuwan B, Nunta-Aree S. http://www.ncbi.nlm.nih.gov/pubmed/?term=38152511
  5. Statin-Induced Necrotizing Autoimmune Myopathy: Case Report of a Patient under Chronic Treatment. Case reports in medicine 2023; 2023:6550473 Bellofatto IA, Sessarego M, Tirandi A et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38145276
  6. Influence of pharmacogenetics on the diversity of response to statins associated with adverse drug reactions. Adv Lab Med 2023; 4:341-352 Sainz de Medrano Sainz JI, Brunet Serra M. http://www.ncbi.nlm.nih.gov/pubmed/?term=38106499
  7. Intolerance upon statin rechallenge: A systematic review and meta-analysis of randomized controlled trials. PLoS One 2023; 18:e0295857 Kraut R, Wierenga F, Molstad E et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38128013
  8. High-throughput target trial emulation for Alzheimer's disease drug repurposing with real-world data. Nature communications 2023; 14:8180 Zang C, Zhang H, Xu J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38081829
  9. SLCO1B1 functional variants and statin-induced myopathy in people with recent genealogical ancestors from Africa: a population-based real-world study. medRxiv 2023; Yee SW, Haldar T, Kvale M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38076949
  10. Inflammatory Myositis Following Statin Use in a Patient With Untreated Hypothyroidism. Cureus 2023; 15:e48463 Renteria M, Jilani M, Brockman MJ, Davis HE. http://www.ncbi.nlm.nih.gov/pubmed/?term=38073998
  11. Retracted: Related Factors of Cerebral Hemorrhage after Cerebral Infarction and the Effect of Atorvastatin Combined with Intensive Nursing Care. Comput Math Methods Med 2023; 2023:9817935 Methods In Medicine CAM. http://www.ncbi.nlm.nih.gov/pubmed/?term=38094432
  12. Identical twins with statin-associated anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibody-positive autoimmune myopathy. Scandinavian journal of rheumatology 2023:1-2 Mali M, Pirilä L, Perander L et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38090763
  13. Effect of statin treatment on metabolites, lipids and prostanoids in patients with Statin Associated Muscle Symptoms (SAMS). PLoS One 2023; 18:e0294498 Garrett TJ, Puchowicz MA, Park EA et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38100464
  14. Unveiling the Rare Complication: Statin-Induced Immune-Mediated Necrotizing Myopathy. Am J Case Rep 2023; 24:e941387 Chowdhury FH, Mahneva O, Maharaj M, Marciales W. http://www.ncbi.nlm.nih.gov/pubmed/?term=38087774
  15. Potential role of geranylgeraniol in managing statin-associated muscle symptoms: a COVID-19 related perspective. Front Physiol 2023; 14:1246589 Tan B, Chin KY. http://www.ncbi.nlm.nih.gov/pubmed/?term=38046949
  16. Efficacy and Safety of Statin Treatment in Children with Familial Hypercholesterolemia: Outcomes of 20 Years of Experience. Journal of clinical medicine 2023; 12 Motkowski R, Abramowicz P, Kubalska J et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38068249
  17. Association of HMGCR inhibition with rheumatoid arthritis: a Mendelian randomization and colocalization study. Frontiers in endocrinology 2023; 14:1272167Ma L, Du Y, Ma C, Liu M. http://www.ncbi.nlm.nih.gov/pubmed/?term=38047111
  18. New clarity for managing statin intolerance in diabetes. The lancet. Diabetes & endocrinology 2023; Hegele RA. http://www.ncbi.nlm.nih.gov/pubmed/?term=38061374
  19. ASSOCIATION OF SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1 GENE POLYMORPHISM WITH RESPONSE TO ATORVASTATIN AND ASSOCIATED MYOPATHY IN IRAQI DYSLIPIDEMIA PATIENTS. Pol Merkur Lekarski 2023; 51:496-503 Dheyaa Aziz N, Abbood SH, Al-Mayali AH, Hadi NR. http://www.ncbi.nlm.nih.gov/pubmed/?term=38069850
  20. Trends in Upper Gastrointestinal Bleeding in Patients on Primary Prevention Aspirin: A Nationwide Emergency Department Sample Analysis, 2016-2020. Am J Med 2023; 136:1179-1186.e1171 Li DK, Laine L, Shung DL. http://www.ncbi.nlm.nih.gov/pubmed/?term=37696350

Stroke and CNS

  1. Atorvastatin mitigates memory deficits and brain monocyte infiltration in chronic hypercholesterolemia. Aging 2023; 15Gong F, Shi Q, Mou X et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38048213
  2. Statin use moderates APOE's and CRP's associations with dementia and is associated with lesser dementia severity in ε4 carriers. Alzheimer's & dementia : the journal of the Alzheimer's Association 2023; Royall DR, Palmer RF. http://www.ncbi.nlm.nih.gov/pubmed/?term=38055626
  3. Statins and cognitive decline in patients with Alzheimer's and mixed dementia: a longitudinal registry-based cohort study. Alzheimer's research & therapy 2023; 15:220 Petek B, Häbel H, Xu H et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38115091
  4. Make My Day: primary prevention of stroke using engaging everyday activities as a mediator of sustainable health – a randomised controlled trial and process evaluation protocol. BMJ Open 2023; 13:e072037 Patomella AH, Guidetti S, Hagströmer M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38056945
  5. Retracted: Related Factors of Cerebral Hemorrhage after Cerebral Infarction and the Effect of Atorvastatin Combined with Intensive Nursing Care. Comput Math Methods Med 2023; 2023:9817935 Methods In Medicine CAM. http://www.ncbi.nlm.nih.gov/pubmed/?term=38094432
  6. Enhanced Neuroprotective Synergy of Atorvastatin and Magnesium L-Threonate in a Rat Model of Alzheimer's Disease Induced by Aluminum Chloride. Cureus 2023; 15:e48400 Gangoda DM, Saiyed MS, Pathan SR et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38074017
  7. Protective Effects Against Dementia Undergo Different Statin Type, Intensity, and Cumulative Dose in Older Adult Type 2 Diabetes Mellitus Patients. Journal of the American Medical Directors Association 2023; Sun M, Chen WM, Wu SY, Zhang J. http://www.ncbi.nlm.nih.gov/pubmed/?term=38128583
  8. Real-world effectiveness and safety of evolocumab in very high-risk atherosclerotic cardiovascular disease patients with acute ischemic stroke. Journal of thrombosis and thrombolysis 2023; Zhang T, Zhang Y, Yang Y et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38063944

Triglycerides/HDL

  1. Comparison of the efficacy and safety of Shanhuang Jiangzhi tablets and atorvastatin in the treatment of patients with hyperlipidaemia. J Health Popul Nutr 2023; 42:143 Sun G, Liang X. http://www.ncbi.nlm.nih.gov/pubmed/?term=38098069
  2. Statin treatment remodels the HDL subclass lipidome and proteome in hypertriglyceridemia. Journal of lipid research 2023:100494 Chapman MJ, Orsoni A, Mellett NA et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38160756

Trials

  1. Eicosapentaenoic and docosahexaenoic acid supplementation and coronary artery calcium progression in patients with coronary artery disease: A secondary analysis of a randomized trial. Atherosclerosis 2023; 387:117388 Hariri E, Asbeutah AA, Malik A et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38056242
  2. Differential effect of atorvastatin and pravastatin on thoracic spine attenuation: A sub-analysis of a randomized clinical trial. Atherosclerosis 2023; 388:117425 Raggi P, Takyar FM, Gadiyaram V et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38109819
  3. Make My Day: primary prevention of stroke using engaging everyday activities as a mediator of sustainable health – a randomised controlled trial and process evaluation protocol. BMJ Open 2023; 13:e072037 Patomella AH, Guidetti S, Hagströmer M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38056945
  4. Statin therapy in patients with early-stage autosomal dominant polycystic kidney disease: Design and baseline characteristics. Contemporary clinical trials 2023:107423 Gitomer BY, Wang W, George D et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38151173
  5. The relationship between plasma cystatin C, mortality and acute respiratory distress syndrome subphenotype in the HARP-2 trial. Crit Care Resusc 2022; 24:251-258 McKelvey MC, Bradbury I, McDowell C et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38046206
  6. The potential benefit of statin prescription based on prediction of treatment responsiveness in older individuals: An application to the PROSPER randomised controlled trial. Eur J Prev Cardiol 2023; Nguyen TL, Trompet S, Brodersen JB et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38085032
  7. The antihyperlipidemic effect of a combined supplement of standardized dry extracts of amla (Emblica officinalis), walnut (Juglans regia), olive (Olea europaea) and red yeast rice (Monascus purpureus) powder: Reduction in circulatory low-density lipoprotein-cholesterol (LDL-C) and remnant cholesterol (RC) levels in patients with hypercholesterolemia. Frontiers in pharmacology 2023; 14:1280234 Hermans MP, Dierckxsens Y, Janssens I et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38089061
  8. Rationale and design of a randomized controlled trial: The effect of intensive lipid-lowering therapy with PCSK9 inhibitor on endothelial-coverage of stent strut after percutaneous coronary intervention (PCI) for patients with acute coronary syndrome (ACS): Optical coherence tomography (OCT) study (PIECES-OCT study). Heliyon 2023; 9:e22222 Yin Z, Li ZF, Zhang WJ et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38045163
  9. Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial. Hepatol Commun 2023; 7 Kronborg TM, Schierwagen R, Trošt K et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38051553
  10. Effect of systemic atorvastatin on bone regeneration in critical-sized defects in hyperlipidemia: an experimental study. International journal of implant dentistry 2023; 9:50 Öztürk K, Kuzu TE, Ayrıkçil S et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38097856
  11. Effect of three-day atorvastatin administration on coagulation factors in patients with prior venous thromboembolism and healthy subjects. A preliminary study. Journal of cardiovascular pharmacology 2023; Stępień K, Żółciński M, Ząbczyk M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38117119
  12. Comparison of the efficacy and safety of Shanhuang Jiangzhi tablets and atorvastatin in the treatment of patients with hyperlipidaemia. J Health Popul Nutr 2023; 42:143 Sun G, Liang X. http://www.ncbi.nlm.nih.gov/pubmed/?term=38098069
  13. Statin treatment remodels the HDL subclass lipidome and proteome in hypertriglyceridemia. Journal of lipid research 2023:100494Chapman MJ, Orsoni A, Mellett NA et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38160756
  14. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. The lancet. Diabetes & endocrinology 2023; Ray KK, Nicholls SJ, Li N et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38061370
  15. The evaluation of atorvastatin as an adjunct to fluconazole for the anti-fungal prophylaxis in acute myeloid leukemia: a multicenter, triple-blinded, randomized clinical trial. Naunyn-Schmiedeberg's archives of pharmacology 2023; Saber-Moghaddam N, Nodeh MM, Ghavami V et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38095652
  16. Getting a CLEARER Picture: Bempedoic Acid and Cardiovascular Outcomes in Patients with Statin Intolerance. Southern medical journal 2024; 117:23-24 Campbell LA, Ammon JP, Jackson CD. http://www.ncbi.nlm.nih.gov/pubmed/?term=38151247
  17. Using Artificial Intelligence to Semi-Quantitate Coronary Calcium as an 'Incidentaloma' on Non-Gated, Non-Contrast CT Scans, A Single-Center Descriptive Study in West Michigan. Spartan Med Res J 2023; 8:89132 Kerndt CC, Chopra R, Weber P et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38084339

Women and elderly

  1. Age- and sex-based heterogeneity in coronary artery plaque presence and burden in familial hypercholesterolemia: A multi-national study. Am J Prev Cardiol 2024; 17:100611 Nasir K, Mszar R, Cainzos-Achirica M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38125206
  2. Atorvastatin exerts dual effects of lesion regression and ovarian protection in the prevention and treatment of endometriosis. Eur J Pharmacol 2023:176261 Qin X, Wang Q, Xu D et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38141938
  3. The potential benefit of statin prescription based on prediction of treatment responsiveness in older individuals: An application to the PROSPER randomised controlled trial. Eur J Prev Cardiol 2023; Nguyen TL, Trompet S, Brodersen JB et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38085032
  4. Impact of influenza, herpes zoster, and pneumococcal vaccinations on the incidence of cardiovascular events in subjects aged over 65 years: a systematic review. Geroscience 2023; 45:3419-3447 Addario A, Célarier T, Bongue B et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=37269492
  5. Effects of Race and Gender Classifications on Atherosclerotic Cardiovascular Disease Risk Estimates for Clinical Decision-Making in a Cohort of Black Transgender Women. Health Equity 2023; 7:803-808 Poteat T, Lett E, Rich AJ et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38076214
  6. Aspirin use for primary prevention in older adults. J Am Geriatr Soc 2023; 71:3927-3929 Luepker RV, Van't Hof JR, Eder M et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=37596891
  7. New Statin Use, Mortality and First Cardiovascular Events in Older US Veterans by Frailty Status. J Am Geriatr Soc 2023; Orkaby AR, Lu B, Ho YL et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38055194
  8. Protective Effects Against Dementia Undergo Different Statin Type, Intensity, and Cumulative Dose in Older Adult Type 2 Diabetes Mellitus Patients. Journal of the American Medical Directors Association 2023; Sun M, Chen WM, Wu SY, Zhang J. http://www.ncbi.nlm.nih.gov/pubmed/?term=38128583
  9. Statins, Mortality, and Major Adverse Cardiovascular Events Among US Veterans With Chronic Kidney Disease. JAMA network open 2023; 6:e2346373 Barayev O, Hawley CE, Wellman H et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38055276
  10. Statin Use and the Risk of Venous Thromboembolism in Women Taking Hormone Therapy. JAMA network open 2023; 6:e2348213 Davis JW, Weller SC, Porterfield L et al. http://www.ncbi.nlm.nih.gov/pubmed/?term=38100102

 

 

 
 

More Information

This monthly newsletter will keep you up to date with a curated list of recent publications relevant to the primary prevention of atherosclerosis.

Want more information? 

  1. Follow Dr. Lansberg on Twitter for live updates
  2. Subscribe to Dr. Lansberg's mailing list for additional newsletters

 

 
 

Copyright © 2024 International Atherosclerosis Society, All rights reserved

 

 

 

מידע כללי
  • מי אנחנו
  • ועד האיגוד
  • כניסת חברים
  • הצטרפות / תשלום דמי חבר
  • תקנון החברה
  • צור קשר
  • ארכיון
חדשות מאתר e-MEd
  • האם פרופיל השומנים מנבא סיכון להישנות סרטן בלוטת תריס? (J Clin Endocrinol Metab)
  • מה בין רמות טריגליצרידים ובין הסיכון לדיכאון? (PLoS One)
  • הטיפ השבועי עם פרופ' איתמר רז: סטטינים לכולם?
  • הגדלת צריכת חומצות שומן אומגה שלוש עשויה לשפר חומרת אקנה (J Cosmetic Dermatol)
לאתר עמותת לכ"ם
לדף הפייסבוק של עמותת לכ"ם

נותנות החסות לאיגוד:

  • צור קשר
  • תנאי שימוש
  • עדכונים מהתעשייה
  • ארכיון
מופעל על ידי e-med.co.il
© החברה לחקר מניעה וטיפול בטרשת עורקים | כל הזכויות שמורות
גלילה לראש העמוד